WO2021249960A1 - Compositions comprising narcissus spp. plant extract and use thereof - Google Patents
Compositions comprising narcissus spp. plant extract and use thereof Download PDFInfo
- Publication number
- WO2021249960A1 WO2021249960A1 PCT/EP2021/065200 EP2021065200W WO2021249960A1 WO 2021249960 A1 WO2021249960 A1 WO 2021249960A1 EP 2021065200 W EP2021065200 W EP 2021065200W WO 2021249960 A1 WO2021249960 A1 WO 2021249960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- narcissus
- composition
- plant
- narcissus spp
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 182
- 241000234479 Narcissus Species 0.000 title claims abstract description 175
- 239000000419 plant extract Substances 0.000 title description 77
- 239000000284 extract Substances 0.000 claims abstract description 128
- 241000196324 Embryophyta Species 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 64
- 239000004480 active ingredient Substances 0.000 claims abstract description 38
- 230000004584 weight gain Effects 0.000 claims abstract description 21
- 235000019786 weight gain Nutrition 0.000 claims abstract description 21
- 210000001789 adipocyte Anatomy 0.000 claims description 117
- 208000008589 Obesity Diseases 0.000 claims description 75
- 235000020824 obesity Nutrition 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 244000223072 Narcissus jonquilla Species 0.000 claims description 49
- 235000013862 Narcissus jonquilla Nutrition 0.000 claims description 49
- 210000000577 adipose tissue Anatomy 0.000 claims description 49
- 206010033307 Overweight Diseases 0.000 claims description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 47
- 235000020825 overweight Nutrition 0.000 claims description 44
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 42
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 41
- 150000002632 lipids Chemical class 0.000 claims description 40
- 230000004069 differentiation Effects 0.000 claims description 39
- 230000001276 controlling effect Effects 0.000 claims description 37
- 239000004615 ingredient Substances 0.000 claims description 36
- 230000001737 promoting effect Effects 0.000 claims description 35
- 239000002537 cosmetic Substances 0.000 claims description 34
- 235000013305 food Nutrition 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 230000028327 secretion Effects 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 25
- 230000037380 skin damage Effects 0.000 claims description 24
- 206010016654 Fibrosis Diseases 0.000 claims description 21
- 230000004761 fibrosis Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000035484 Cellulite Diseases 0.000 claims description 20
- 230000036232 cellulite Effects 0.000 claims description 20
- 206010040925 Skin striae Diseases 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 206010025282 Lymphoedema Diseases 0.000 claims description 15
- 208000002502 lymphedema Diseases 0.000 claims description 15
- 230000030968 tissue homeostasis Effects 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 244000230712 Narcissus tazetta Species 0.000 claims description 12
- 239000012675 alcoholic extract Substances 0.000 claims description 12
- 241001532689 Narcissus pseudonarcissus Species 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 239000000344 soap Substances 0.000 claims description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 9
- 102000016942 Elastin Human genes 0.000 claims description 9
- 108010014258 Elastin Proteins 0.000 claims description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 9
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 9
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 9
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 9
- 229920002549 elastin Polymers 0.000 claims description 9
- 239000002417 nutraceutical Substances 0.000 claims description 9
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 claims description 8
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 230000002500 effect on skin Effects 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 230000006372 lipid accumulation Effects 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 7
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 7
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 208000010706 fatty liver disease Diseases 0.000 claims description 7
- 230000004130 lipolysis Effects 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 claims description 6
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 210000001593 brown adipocyte Anatomy 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- 108010078606 Adipokines Proteins 0.000 claims description 4
- 102000014777 Adipokines Human genes 0.000 claims description 4
- 239000000478 adipokine Substances 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 239000003094 microcapsule Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 210000000636 white adipocyte Anatomy 0.000 claims description 4
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 239000004531 microgranule Substances 0.000 claims description 3
- 229960003742 phenol Drugs 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 description 47
- 230000000694 effects Effects 0.000 description 45
- 238000009472 formulation Methods 0.000 description 33
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 26
- 239000003925 fat Substances 0.000 description 26
- 235000019197 fats Nutrition 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 235000011187 glycerol Nutrition 0.000 description 16
- 238000009825 accumulation Methods 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 230000035508 accumulation Effects 0.000 description 14
- -1 discutient Substances 0.000 description 14
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 13
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 13
- 229960001948 caffeine Drugs 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 238000007796 conventional method Methods 0.000 description 12
- 208000030159 metabolic disease Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 210000000229 preadipocyte Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 210000000593 adipose tissue white Anatomy 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000002137 ultrasound extraction Methods 0.000 description 8
- 210000001217 buttock Anatomy 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003636 conditioned culture medium Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000006072 paste Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 206010049752 Peau d'orange Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 235000012149 noodles Nutrition 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 230000002366 lipolytic effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000013580 sausages Nutrition 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 206010007882 Cellulitis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031439 Striae Distensae Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- ITBPIKUGMIZTJR-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol Chemical compound OCN(CO)CO ITBPIKUGMIZTJR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000000476 thermogenic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RSINTYZGAWHRBE-UHFFFAOYSA-N 1,3-thiazole-4,5-dione Chemical compound O=C1SC=NC1=O RSINTYZGAWHRBE-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JEFDYHWPYRIMCZ-UHFFFAOYSA-N 8-(3-methylbutyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCC(C)C)N2 JEFDYHWPYRIMCZ-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 101150008656 COL1A1 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241001094255 Elytraria Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 101150109526 Sirt6 gene Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003919 adipocyte function Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000004982 adipose tissue macrophage Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229940046102 narcissus pseudonarcissus extract Drugs 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001763 pro-adipogenic effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000025488 response to cold Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention relates to a method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject. Furthermore, the present invention refers to the use of such composition for controlling weight gain of a subject and to such composition for use in a method for of controlling weight gain of a subject.
- the present invention further relates to com postions comprising Narcissus spp. plant extract and use thereof. It further relates to compositions for preventing and/or treating obesity and/or metabolic syndrome comprising Narcissus spp. plant extract. Moreover, the present invention relates to compositions for preventing and/or treating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract. The Narcissus spp.
- plant extract which is the active ingredient of the present invention, may inhibit an increase in the number of adipocytes and lipid accumulation by inhibiting adipocyte differentiation, inhibit excessive secretion of adipocyte-derived lipids, is a safe substance having no skin irritation and cytotoxicity, and is useful for a pharmaceutical composition, a food composition, a skin external preparation composition and a cosmetic composition for the prevention, amelioration and treatment of obesity, metabolic syndrome and, more generally for improving the overall skin properties.
- Obesity refers to a phenomenon in which excess calories are accumulated as fats in the body by ingesting more calories than the calories consumed.
- the World Health Organization (WHO) reported that about 400 million people in the world over the age of 15 are classified as obese, and 1.6 billion people are overweight (September 2006). In line with this trend, obesity has emerged as a severe social problem, not just an individual disease. Obesity is known to be caused by genetic factors, environmeltal and/or lifestyle factors resulting from westernized dietary habits, and psychological factors resulting from stress, but the exact cause or mechanism of obesity has not been clearly identified.
- the goals of obesity treatment are broadly divided into two.
- One goal is to lose weight by burning excess fat, and a further goal is to improve metabolic imbalance.
- Abdominal obesity is closely related to symptoms such as insulin resistance, type 2 diabetes, hypertension, and lipid metabolism, and acts as a strong risk factor for early arteriosclerosis, ischemic heart disease, and cerebrovascular disease (Kopleman P.G., Nature, 404, 2000; Manson et al., New England J. Med., 333, 1995; Must et al., JAMA, 282, 1999).
- the treatment of obesity aims not only at losing weight but also at ameliorating metabolic abnormalities by early eliminating factors that cause cardiovascular disease. Studies focused on suppressing obesity by controlling dietary intake control and energy consumption have also been actively conducted.
- hypothalamus, motor nervous, autonomic nervous, and peripheral nervous systems are all involved in regulating food intake behaviors, and the central nervous system, especially the hypothalamus, plays an important role in the etiology of obesity.
- Typical factors secreted from the hypothalamus include neuropeptide Y, POMC/CART, melanocortin receptor, norepinephrine, serotonin, and the like.
- Current strategies for developing obesity therapeutic agents include reducing food intake, inhibiting calorie absorption, promoting exothermic reactions, regulating energy metabolism, and regulating signal transduction through the nervous system (Mi-Jung Park, Korean J Pediatr 48(2), 2005).
- the most representative drugs include XenicalTM (Roche Pharmaceuticals, Switzerland), ReductilTM (Abbott, USA), ExoliseTM (Arkopharma, France), and the like, but cause adverse effects such as cardiac diseases, respiratory diseases, neurological diseases and the like.
- the persistence of efficacy thereof is low. Accordingly, the search for safer and more effective anti-obesity substances is ongoing.
- Caffeine is a well known slimming ingredient (also designatable as slimming agent) which can be incorporated in many formulation forms such as topical, nutraceutical compositions.
- caffeine is an alkaloid, enables to prevent the excessive accumulation of fat in adipose tissue, to stimulate the lipolysis, to degrade triglycerides and, thus, it takes part in the reduction of fat-related skin damages such as cellulitis for example.
- Fat stored in adipocytes is used as an important energy source in the body, but as obesity progresses, the number of adipocytes increases and adipocytes differentiate. As adipocytes differentiate, the synthesis of triglycerides increases.
- triglycerides accumulated and stored in adipocytes increase the size of adipocytes, and the diameter of adipocytes may increase about 20 times due to the storage of fat therein, and as a result, the cell volume increases several thousand times.
- This size of adipocytes may be controlled by dietary control, but the process in which new preadipocytes differentiate into adipocytes is not effectively controlled by dietary control. Thus, for the fundamental treatment or inhibition of obesity, it is important to control the adipocyte differentiation process of adipocytes.
- brown adipose tissue Another way to tackle obesity, is to stimulate the “browning” of white adipose tissue (WAT).
- WAT white adipose tissue
- brown adipose tissue (only present in the first few months of human life) contain cells with smaller fat droplets and are more energetically active due to their greater number of mitochondria.
- Brown adipocytes express a protein called uncoupling protein 1 (UCP-1 ) localized to the mitochondria membranes where it short-circuits the pathway to produce energy. This energy is then dissipated for heat production in response to cold. Thereby, heat is produced while energy is consumed which eventually leads to the elimination of fat deposits.
- UCP-1 uncoupling protein 1
- Adipose tissue macrophages represent the most abundant class of immune cells in adipose tissue and are involved in the regulation of several regulatory physiological processes, such as tissue remodeling and insulin sensitivity. It has been shown that macrophages recruited from blood monocytes are critical components of the generation of adipose tissue inflammation, but their proliferation plays a role in the early stages of obesity and in sustaining adipose tissue inflammation (Russo and Lumeng, Immunology 2018).
- a disproportionately increase of pro-inflammatory macrophages in WAT is associated with obesity and compromises the adipose tissue homeostasis by promoting the adipocyte hypertrophy, the altered secretion profile of adipocytes, the metabolic dysfunction and the excessive deposition of collagen fibers around adipocytes, so called peri-adipocyte fibrosis, which reinforce the macrophage increase in adipose tissue and perpetuate a vicious cycle with the maintenance of fibro-inflammation in adipose tissue of an obese or an overweight person. Additionally, it is also known that the adipose tissue of obese or an overweight person is mainly constituted by enlarged adipocytes.
- adipocyte enlargement was significantly decreases the dermal elasticity (Ezure et al., Experimental dermatology, DO1 10.1111 ; 2015). More generally, it has been shown that obesity is an aggravating factor for skin properties (Mori et al., Lipids in Health Disease, DO1 10.1186; 2017). Indeed, the authors showed a reduction of the moisturizing and barrier functions of the skin, and an inflammation-like symptom including redness and roughness.
- adipocytes contribute to various skin functions and their ability to perform many of their functions is influenced by their stored lipids. Indeed, it is agreed that dermal fibrosis involves the deposition of excessive extracellular matrix and the loss of adipocytes.
- Narcissus spp. plants are perennial plants belonging to the Narcissus family and are collectively referred to as narcissus.
- Narcissus is planted as bulbs in winter and blooms mainly in spring.
- Bulbs of narcissus are toxic and are used as a disinfectant for boils or swelling, flowers thereof are used to produce perfumed oil, and scaly stems thereof are used as a therapeutic agent as an expectorant of whooping cough.
- microniosomes, including narcissus bulbs exhibit a wound healing effect by promoting the proliferation and migration of fibroblasts (Ramaesh M et al., Daru 2018 Sep 12.
- KR-A 10-2016-0114794 discloses that a narcissus bulb extract has the effects of improving skin elasticity, reducing wrinkles, and reducing skin irritation
- KR-B 10-1807978 discloses a composition containing a Narcissus spp.-derived peptide that activates Sirt6.
- the adipocyte differentiation regulatory effect suggested by the present invention has not yet been reported.
- an extract of the aerial parts of Narcissus spp. plant can be used as a slimming ingredient.
- a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant can be used for preventing and/or treating obesity, for preventing and/or treating fat-related disorders in adipose tissue, for preventing and/or alleviating or treating the fat-related skin disorders or damages.
- the at least one extract of the aerial parts of Narcissus spp. plant is useful to comply with the improvement of the overall skin properties.
- an aspect of the present invention is a method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject.
- the method may be any method, including a cosmetic method (also: non-pharmaceutical, non-therapeutic) or a therapeutic (also: pharmaceutical) method.
- One object of the present invention is to provide a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
- the extract of aerial parts of a Narcissus spp. is an active slimming ingredient.
- Another object of the present invention is to provide a composition
- a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant for use for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages seleted from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight- related skin.
- Another object of the present invention relates to a cosmetic use of a composition
- a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for treating or alleviating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
- Another object of the present invention is to provide a pharmaceutical composition for preventing and/or treating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract (e.g.,an extract of the aerial parts of Narcissus spp. plant).
- the method is a method of preventing, ameliorating, or treating obesity and/or metabolic syndrome.
- Another object of the present invention is to provide a skin external preparation composition for preventing and/or treating obesity comprising a Narcissus spp. plant extract.
- Still another object of the present invention is to provide a food composition for preventing or ameliorating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract.
- Yet another object of the present invention is to provide a cosmetic composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant).
- a Narcissus spp. plant extract e.g., an extract of the aerial parts of Narcissus spp. plant.
- Still another object of the present invention is to provide a food or nutraceutical composition
- a food or nutraceutical composition comprising (or consisting of) an extract of the aerial parts of Narcissus spp. plant for preventing or ameliorating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for preventing or ameliorating metabolic syndrome.
- a further object of the present invention is to provide a cosmetic method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema and striae, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
- Still yet another object of the present invention is to provide a method of preventing, ameliorating, or treating obesity and/or metabolic syndrome using a composition comprising (or consisting of) a Narcissus spp. plant extract.
- the present invention relates to compositions for preventing, ameliorating, and treating obesity or fat-related disorders and/or metabolic syndrome comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition, a skin external preparation composition, a cosmetic composition and a food (or nutraceutical) composition, which each comprise a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) as an active ingredient.
- a Narcissus spp. plant extract e.g., an extract of the aerial parts of Narcissus spp. plant
- compositions are highly safe for humans without having skin irritation and cytotoxicity, and may inhibit adipocyte differentiation, reduce the number of adipocytes, and may effectively inhibit lipid accumulation and excessive secretion of adipocyte-derived lipids.
- the compositions enable to regulate the impaired metabolic and endocrine functions of the adipose tissue. It will be understood that, in a composition consisting of Narcissus spp., the composition is the extract.
- An aspect of the present invention relates to a composition
- a composition comprising (or consisting of) at least one Narcissus spp. plant extract (e.g., extract of the aerial parts of Narcissus spp. plant) as an active slimming ingredient.
- An aspect of the present invention provides a pharmaceutical composition for preventing and/or treating obesity or metabolic syndrome comprising at least one extract of a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant).
- the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo- Narcissus L.
- the Narcissus spp. plant is Narcissus jonquilla L.
- extract refers to products such as liquid products obtained by immersing materials including plants in various solvents, and then performing extraction and fractionation in a room temperature or elevated temperature state for a predetermined time, or solid products obtained by removing the solvents from the liquid products.
- extract may be interpreted as including all dilutions of the products, concentrates thereof, crude products thereof, and purified products thereof.
- the “Narcissus spp. plant extract” is obtained by extraction from the leaf, flower, stem, root and the like of the Narcissus spp. plant, preferably the flower, leaf, and stem of the Narcissus spp. plant. Prefreably, it is at least one part of the aerial part of the Narcissus spp. plant.
- the “Narcissus spp. plant extract” is obtained by extraction from the aerial parts of the Narcissus spp. plant, preferably from the leaf, flower, stem and the like of the Narcissus spp. plant.
- the aerial part of the Narcissus spp. plant may be selected from the leaves, the stems, the flowers, or a combination of two or more thereof.
- the aerial part of the Narcissus spp. plant comprises stems and/or flowers.
- the aerial part of Narcissus spp. is characterized in that:
- the Narcissus spp. plant extract may be obtained by extraction with water or any organic solvent.
- the organic solvent may preferably be water, a polar solvent, or a non-polar solvent, but the solvent is not limited thereto as long as an extract having the effects of inhibiting adipocyte differentiation, inhibiting lipid accumulation of adipocytes and excessive secretion of adipocyte-derived lipids, restoring the adipose tissue homeostasis, alleviating the overweight skin damages and promoting the firmness of the overweight-related skin may be obtained.
- an alcohol contained in a hydroalcoholic or alcoholic extract may be any alcohol.
- an alcohol contained in a hydroalcoholic or alcoholic extract is selected from the group consisting of ethanol, methanol, propanol, butanol, pentanol, phenol, glycerol, 1 ,3-butylene glycol, propane diol, or a mixture of two or more thereof, in partilcar wherein an alcohol contained in a hydroalcoholic or alcoholic extract is ethanol;
- the organic solvent may preferably be water, a polar solvent, or a non-polar solvent, but the solvent is not limited thereto as long as an extract having the effects in the spirit of the disclosure of the present invention may be obtained.
- the solvent may be water, C1-C4 lower alcohol (e.g., selected from ethanol, methanol, propanol, butanol), pentanol, phenol, glycerol, 1 ,3-butylene glycol, propane diol or a mixture of two or more thereof.
- the solvent may be a mixture of water and ethanol or a mixture of water and methanol.
- the solvent may be an alcohol selected from methanol and ethanol.
- the solvent may be a mixture of water and ethanol.
- the at least one extract of aerial parts of Narcissus spp. is an aqueous extract which is obtained by extracting the aerial parts of Narcissus spp. with hot water of a temperature of 25 to 200°C, of 50 to 175°C, of 60 to 150°C, of 70 to 140°C, of 80 to 130°C, or of 90 to 120°C.
- the temperature used in this context may in the range of 50 to 70°C, of 60 to 90°C, of 90 to 100°C, of 100 to 110°C, of 110 to 120°C, or of 100 to 150°C.
- extracting the aerial parts of Narcissus spp. with hot water is conducted under reflux.
- Such extraction under reflux may be conducted 1 time (i.e., once), 2 times (i.e., twice),
- times in this context may also be designated as “in extraction cycles”
- extracting the aerial parts of Narcissus spp. with hot water is conducted 1 time, 2 times or 3 times, in particular
- Extraction under reflux may be conducted for a time sufficient for extraction.
- one extraction (cycle) may be conducted for a time range of from 1 min to 24 h, of from 5 min to 12 h, of from 10 min to 6 h, of from 15 min to 3 h, of from 15 min to 1 h, or of from 15 min to 45 h, or of from 20 min to 35 h.
- the total time for extraction may be performed within 5 min to 24 h, of from 10 min to 12 h, of from 15 min to 12 h, of from 30 min to 6 h, of from 90 min to 5 h, of from 2 h to 4 h, of from 2 h to 3 h.
- extracting the aerial parts of Narcissus spp. with hot water is conducted at 90 to 120°C, 3 times under reflux, wherein each reflux may last 20 to 35 min, and the procedure optionally is conducted during 2 hours.
- a method for obtaining the extract is not particularly limited as long as it may provide an extract having the effects of inhibiting adipocyte differentiation and inhibiting lipid accumulation of adipocytes or excessive secretion of adipocyte-derived lipids, restoring the adipose tissue homeostasis, alleviating the overweight skin damages and promoting the firmness of the overweight-related skin.
- a method for obtaining the extract is not particularly limited as long as it may provide an extract having the effects in the spirit of the disclosure of the present invention. Examples of the extraction method may include hot water extraction, cold water extraction, ultrasonic extraction, and reflux cooling extraction methods. Extraction may preferably be performed by the ultrasonic extraction method.
- the ultrasonic extraction is a method of extracting useful components from various natural materials at room temperature by a physical force rather than chemical force using a vibrating element having a vibration frequency of 20,000 times or more per second.
- the ultrasonic extraction has the advantage of being able to extract high concentrations of active ingredients from natural materials at room temperature without destroying the active ingredients.
- the ultrasonic extraction may be performed on the dried powder of the aerial part of a Narcissus spp. plant using a 60% to 80% (by volume) ethanol solution at room temperature for 24 to 72 hours.
- the ultrasonic extraction may be performed using a 50% to 90% (by volume), preferably a 65% to 75% (by volume) ethanol solution at room temperature for 36 to 60 hours.
- the ultrasonic extraction is performed using a 60 to 80% (by volume), preferably 70% ethanol solution at room temperature for 20 to 50 hours, preferably for 25 to 45 hours, more preferably for 40 hours.
- the active ingredient of the present invention contained in the aerial part of the Narcissus spp. plant, will not be sufficiently extracted. If the ethanol concentration and the extraction time are higher than the upper limits of the above-described ranges, there will be no significant difference in the amount of the active ingredient extracted, impurities will be extracted in addition to the active ingredient, and the efficiency of the extraction process will be reduced.
- the hot-water extract is performed on the dried powder of the aerial parts of the Narcissus spp. plant in purified water at high temperature, preferably 100 to 150°C, more preferably 100 to 130°C, even more preferably 110 to 130°C, most preferably 121 °C, for 20 minutes to 1 hour, preferably 20 minutes to 50 minutes, more preferably 20 minutes to 40 minutes, most preferably 30 minutes.
- the obtained Narcissus spp. plant extract may be concentrated under reduced pressure using, but not limited to, a vacuum concentrator or a rotary vacuum evaporator.
- the extract may be dried through, but not limited to, freeze drying, reduced-pressure, vacuum drying, boiling drying, or spray drying.
- dry extract may be understood in the broadest sense as a dry matter (physical form) without the solvent.
- adipose tissue homeostasis means that the adipose tissue having its normal or healthy state in terms of cell proliferation, cell death, and its metabolic function.
- the term “cellulites” also known as “orange peel”, is characterized by an uneven skin profile affecting the tissue around the thighs, buttocks and hips, the areas where adipose tissue is deposited in the largest amounts in a subject. The dimply appearance is caused by the extension of the fat tissue into the fibrous connective tissue. Larger fat deposits exacerbate this problem as the pressure from the fat onto the connective tissue increases.
- the term “striae or striae distensae”, also known as stretch-marks is a skin defect caused by excessive stretching of the skin in areas with large amounts of adipose fat tissue, such as the breasts, buttocks, abdomen, hips, thighs and underams. They appear first as erythematous linear bands, which turn purple and then white overtime, becoming atrophic and depressed. Overweight, particularly obesity is one of the fastest bringers of striae as it involves rapid growth which the skin is less likely to keep up this evolution.
- the Narcissus spp. plant extract which is an active ingredient of the present invention has the general beneficial effects of restoring or promoting the adipose tissue homeostasis, treating or alleviating the overweight-induced skin damages, particularly by controlling adipogenesis by inhibiting adipocyte differentiation, reducing the number of (mature) adipocytes, inhibiting the accumulation and excessive secretion of (adipocyte-related) lipids, promoting lipolysis of adipocytes, by promoting the conversion of white adipocytes into brown adipocytes, by controlling the structure of the dermal extracellular matrix, by counteracting the inflammation of the adipose tissue and by controlling the secretion of adipokines.
- the extract of the aerial parts of Narcissus spp. according to the present invention can be used as an ingredient to comply with the slimming purposes, more generally to improve the overall skin properties, particularly its physiology and aspect.
- an ethanol extract of an aerial part of a Narcissus spp. plant has the effects of inhibiting an increase in the number of adipocytes by inhibition of adipocyte differentiation and inhibiting lipid accumulation and secretion by inhibiting the production of adipocyte-derived lipids (FIGS. 1 and 10). Therefore, the composition comprising the Narcissus spp.
- plant extract according to the present invention is effective in inhibiting adipocyte differentiation, inhibiting accumulation of adipocyte-derived lipids, and inhibiting excessive secretion of adipocyte-derived lipids, and thus is useful for the prevention, amelioration and treatment of obesity and metabolic syndrome.
- the term "obesity” refers to a condition in which the number of adipocytes is above average and lipids are excessively accumulated in adipocytes.
- the term "metabolic syndrome” refers to a disease caused by obesity or at least over-weight, or at least having a high correlation with them (e.g. obesity).
- the metabolic syndrome may be, but is not necessarily limited to, any one selected from among fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
- the lipid-related metabolic syndrome refers to a disease in which various metabolic syndromes such as diabetes and obesity appear simultaneously in a single person.
- ameliorating obesity refers to suppress, reduce, and eliminate the increase in the number of adipocytes and excessive accumulation of lipids in adipocytes due to excessive adipocyte differentiation in a subject.
- ameliorating metabolic syndrome refers to suppress, reduce, and eliminate metabolic syndrome caused by an increase in the number of adipocytes and excessive accumulation of lipids in adipocytes due to excessive adipocyte differentiation in a subject.
- the term “overweight-related skin damages” refers to the damages caused by the over fat-accumulation within the adipose tissue.
- such damages may include cellulitis, striae, lymphedema, sagginess or softening and tissue fibrosis selected from keloids, scleroderma and hypertrophic scarring.
- the term “fat” and “lipid” have the same meaning and may be understood interchangeably.
- “treating or alleviating the overweight-related skin damages” refers to suppress, reduce or eliminate the aforementioned overweight-related skin damages.
- controlling or regulating refers to the upregulation and/or downregulation of the expression of at least one gene.
- the content of the Narcissus spp. plant extract (e.g., the extract of the aerial parts of Narcissus spp. Plant), which is contained in the above composition, may be, but is not specifically limited to, an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15% by weight, and more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
- a further aspect of the invention relates to a cosmetic or pharmaceutical composition
- a cosmetic or pharmaceutical composition comprising: a. at least one extract of the aerial parts of Narcissus spp. of as defined above (e.g. , as an active slimming ingredient); and b. at least one further cosmetically and/or pharmaceutically acceptable ingredient other than the extract of Narcissus spp., preferably wherein the composition is a composition for topic use selected from the forms selected from the group consisting of a solution, a suspension, an emulsion, a cream, a paste, a gel, a lotion, a powder, a microcapsule, a microgranule, a soap, a surfactant- containing water, an oil, an ointment, and a spray, or wherein the composition is a food or a nutraceutical composition which is administered orally.
- Another aspect of the present invention relates to a method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight- induced skin damages selected cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient as defined above.
- compositions comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant for use for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
- the composition is for use for preventing and/or treating a metabolic syndrome selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid- related metabolic syndrome.
- the method of the present invention is:
- metabolic syndrome for preventing and/or treating a metabolic syndrome, in particular wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid- related metabolic syndrome.
- Another aspect of the invention relates to a cosmetic use of a composition
- a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
- the cosmetic use comprises: preventing the lipid accumulation by regulating the adipocyte differentiation, inhibiting excessive secretion of adipocyte-derived lipids, stimulating adipocytes lipolysis, promoting the conversion of white adipocytes into brown adipocytes by increasing the expression of UCP-1 and/or TFAM, controlling the structure of the dermal extracellular matrix by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin, counteracting or preventing the tissue fibrosis by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin; counteracting or preventing the inflammation of the adipose tissue by inhibiting the secretion of IL-6, counteracting or preventing the inflammation-induced ectopic collagen-l depots formation in the adipose tissue by inhibiting the synthesis of procollagen-l by preadipocytes, controlling the secretion of adipokines from adipose tissue, and a combination of
- the cosmetic use of the composition of the invention is characterized in that:
- the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo-Narcissus L, preferably Narcissus jonquilla L
- the aerial part is selected from the group consisting of the leaves, the stems, the flowers, or a combination of two or more thereof, preferably the stems and the flowers;
- the term "pharmaceutical composition” means a composition prepared for preventing and/or treating disease and may be formulated into various forms according to each conventional method.
- the composition may be formulated into oral dosage forms such as modifier, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., and parenteral dosage forms such as diluents or excipients such as lubricants, wetting agents, flavoring agents, emulsifying agents, suspending agents, preservatives, surfactants, etc.
- it can be formulated and used in the form of external preparations, suppositories, skin external preparations, and sterile injectable solutions.
- the composition of the present invention may be used orally in an oral dosage form.
- the composition of the present invention may be used by a method such as direct application or dispersion to a area such as a thigh, buttocks, or abdomen where a large number of adipocyte are distributed.
- the above application and dispersion are not limited to the above area and may be applied to any area in which adipocytes are developed.
- a pharmaceutically acceptable carrier such as a buffering agent, a painless agent, a solubilizing agent, an isotonic agent, a stabilizer, a base agent, and the like, may be prepared by additionally including a carrier known in the art.
- the term “pharmaceutically acceptable carrier” may refer to a carrier or a diluent that does not interfere with the biological activity and properties of an active ingredient to be injected without stimulating organisms.
- the type of carrier which can be used in the present invention is not particularly limited, and any pharmaceutically acceptable carrier commonly used in the art may be used.
- Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, etc. These may be used alone or in combination with two or more thereof.
- the carrier may include a non-naturally occurring carrier.
- composition of the present invention may be administered in a pharmacologically effective amount.
- pharmacologically effective amount refers to an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects. Effective dosage levels depend on the patient's health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used in combination or concurrently, and other factors well known in the medical field.
- it is generally 0.01 mg to 5000 mg per 1 kg of the body weight of the administered subject and may be dividedly administered once a day or several times a day at predetermined time intervals according to the judgment of a doctor or pharmacist, but is not limited thereto.
- composition of the present invention may be used alone or in combination with other pharmaceutically active compounds exhibiting a prophylactic or therapeutic effect of obesity and/or metabolic diseases (equivalent designatable as disorders) or in an appropriate set.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It is important to administer an amount that can achieve the maximum effect in a minimum amount without causing side effects by taking all of these factors into consideration, and it can be easily decided by a person skilled in the art.
- the pharmaceutical composition comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) of the present invention as an active ingredient
- a Narcissus spp. plant extract e.g., an extract of the aerial parts of Narcissus spp. plant
- it can be used in combination with commonly used antiobestic agent such as locasein that acts on the central nervous system to reduce appetite through activation of the central nervous system to suppress appetite, orlistat that inhibits fat absorption as an antiobestic agent of non-central nervous system, and Liraglutide that is an analogue of GLP-1 (Glucagon-Like Peptide 1 ) as an appetite control substance, and like.
- commonly used antiobestic agent such as locasein that acts on the central nervous system to reduce appetite through activation of the central nervous system to suppress appetite, orlistat that inhibits fat absorption as an antiobestic agent of non-central nervous system
- Liraglutide that is an ana
- the term “administration” refers to introducing the pharmaceutical composition of the present invention to a subject in any suitable manner, and the injection route of the composition of the present invention may be administered via oral or parenteral various routes as long as it can reach the desired tissue.
- the method of administration of the pharmaceutical composition according to the present invention is not particularly limited thereto, and may be in accordance with a method commonly used in the art.
- the composition may be administered orally or parenterally.
- the composition of the present invention may be used by a method such as direct application or dispersion to a area such as a thigh, buttocks, or abdomen where a large number of adipocytes are distributed.
- the pharmaceutical composition according to the present invention can be prepared in various formulations according to the intended administration method.
- the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or several times by dividing the dose.
- the present invention provides a method for preventing and/or treating lipid-related diseases (equivalent designatable as disorders) comprising administering a pharmaceutical composition containing a Narcissus spp. plant extract (e.g., an extract of the aerial parts of the Narcissus spp. plant) to a subject.
- a pharmaceutical composition containing a Narcissus spp. plant extract e.g., an extract of the aerial parts of the Narcissus spp. plant
- the Narcissus spp. plant extract and its preventive and therapeutic effects on obesity and metabolic diseases are as described above.
- the term "subject” may mean all animals including humans who have or are likely to develop obesity and/or metabolic diseases (equivalent designatable as disorders).
- the animals may be mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. in need of treatment for symptoms similar to humans, but are not limited thereto. Humans are preferred.
- a subject in the context of the present invention may be of any age. For instance, a subject may be an adult, an adolescent, or a child, preferably an adult.
- controlling weight gain may be understood in the broadest sense as having an influence on body weight and increase in weight.
- controlling weight gain is reducing weight gain.
- controlling weight gain is minimizing or (essentially) preventing weight gain.
- controlling weight gain is reducing weight of the subject of interest.
- controlling weight gain is having a slimming effect (i.e., serving as an active slimming ingredient).
- controlling weight gain is preventing, ameliorating, or treating obesity and/or metabolic syndrome, and/or restoring the adipose tissue homeostasis, and/or alleviating the overweight skin damages and/or promoting the firmness of the overweight-related skin may be obtained.
- the prevention and/or treatment method of the present invention may specifically include administering the composition in a pharmaceutically effective amount to a subject who has or is at risk of developing obesity and/or metabolic disease.
- the administration method is as described above.
- the prevention may refer to any action of inhibiting or delaying the onset of obesity and/or metabolic diseases (e.g., syndrome and metabolic disorders of the adipose tissue, the overweight-related skin damages), by administering the composition for preventing and/or treating obesity and/or metabolic diseases (equivalent designatable as disorders) according to the present invention to a subject.
- obesity and/or metabolic diseases e.g., syndrome and metabolic disorders of the adipose tissue, the overweight-related skin damages
- the treatment may refer to any action of improving or benefitting the symptoms of obesity and/or metabolic diseases (e.g., syndrome and metabolic disorders of the adipose tissue and/or the overweight-related skin damages) by administering the composition of the present invention to a subject suspected of developing obesity and/or metabolic disease.
- the pharmaceutical composition comprising the Narcissus spp. plant extracts is as described above.
- composition of the present invention may contain a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described active ingredients for administration.
- the carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl Cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- a suitable dosage of the composition of the present invention may vary depending on the condition and weight of the patient, the severity of the disease, the form of the drug, and the time, but may be appropriately selected by a person skilled in the art. Specifically, the dosage of the Narcissus spp. plant extracts may be 50 to 500 mg/Kg.
- the present invention provides a skin external preparation for preventing or ameliorating obesity comprising the Narcissus spp. plant extract.
- the Narcissus spp. plant extract and its preventive and therapeutic effects on obesity are as described above.
- the skin external preparation of the present invention can be used for the purpose of preventing and ameliorating obesity, and the skin external preparation can be generally used for areas such as thighs and buttocks in which cellulite formed by excessive adipocyte differentiation and accumulation of lipids in adipocyte is excessively distributed. It can be applied to any area in which adipocytes are developed, not limited to the above area.
- the skin external preparation according to the present invention may be formulated by containing a medium or base that is acceptable cosmetically or dermatologically.
- a medium or base that is acceptable cosmetically or dermatologically.
- formulations suitable for topical application such as solutions, gels, solids, dough anhydrous products, emulsions obtained by dispersing the oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules, the form of ionic (liposomes) and nonionic vesicle dispersant, or the form of a cream, skin, lotion, powder, ointment, spray, pack or conceal stick. It may be used in the form of a foam or an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.
- the skin external preparation according to the present invention includes fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic Or nonionic emulsifiers, fillers, sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles, or adjuvants commonly used in the field of cosmetics or dermatology as any other ingredients commonly used in cosmetics.
- the adjuvant is introduced in an amount generally used in the field of cosmetology or dermatology.
- the content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15 wt%, and more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
- the present invention provides a food or nutraceutical composition for preventing or ameliorating obesity and/or metabolic syndrome comprising the Narcissus spp. plant extract.
- the Narcissus spp. plant extract and its preventive and therapeutic effects on obesity and metabolic syndrome are as described above.
- the Narcissus spp. plant extracts may be added as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment) and may further include food additives acceptable for food. Since the composition of the present invention uses an extract derived from a natural product as an active ingredient, there is no problem in terms of stability, so there is no significant limitation on the amount of mixing.
- the food or nutraceutic composition of the present invention may include all foods in a conventional sense and may be mixed with terms known in the art, such as functional foods and health functional foods.
- the term 'functional food refers to a food manufactured and processed using raw materials or ingredients having functions useful for the human body according to the (Korean) Health Functional Food Act No. 6727, and the term “functional” refers to ingestion for the purpose of obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
- the term "health functional food” refers to a food manufactured and processed using a specific ingredient as a raw material or a food manufactured and processed by extracting, concentrating, refining, mixing specific ingredients contained in food ingredients as raw materials for the purpose of health supplementation, It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, biological rhythm control, disease prevention and recovery, etc. by the above ingredients, and the health food composition can perform functions to prevent diseases (equivalent designatable as disorders) and prevent diseases (equivalent designatable as disorders), etc.
- compositions of the present invention can be used for the prevention and/or amelioration of obesity and/or metabolic diseases (equivalent designatable as disorders).
- compositions comprising the Narcissus spp. plant extracts of the present invention as an active ingredient may be prepared by mixing suitable other auxiliary ingredients and known additives that may be contained in food according to the choice of a person skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, and the like. Furthermore, foods can be prepared by adding the extract and fraction thereof according to the present invention as a main component to other extracts, tea, jelly, juice, and the like.
- foods that can be applied to the present invention include, for example, special nutritional foods (e.g., milk formula, infants/baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), health supplement foods, seasoned foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, sweets (e.g., snacks), dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.) ), beverages (e.g., fruit, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.).
- special nutritional foods e.g., milk formula, infants/baby food, etc.
- processed meat products e.g., fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.
- the content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15% by weight, more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
- the health functional food composition of the present invention may contain various sweetening agents, flavoring agents, natural carbohydrates, and the like as an additional component, as in ordinary beverages.
- the health functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agent used in carbonated beverages, etc.
- it may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, and vegetable beverage.
- the present invention provides a cosmetic composition for preventing or ameliorating obesity comprising a the Narcissus spp. plant extract (e.g., an extract of the aerial parts the Narcissus spp. plant).
- the Narcissus spp. plant extract and its preventive and therapeutic effects on obesity are as described above.
- the cosmetic composition of the present invention can be used for the purpose of preventing and ameliorating obesity.
- the cosmetic composition can be generally used for areas such as thighs and buttocks in which cellulite formed by excessive adipocyte differentiation and accumulation of lipids in adipocyte is excessively distributed, and the cosmetic composition is not limited to the area and can be applied to any area in which adipocytes are developed.
- the component contained in the "cosmetic composition” may include ingredients commonly used in cosmetic compositions in addition to the active ingredient.
- it contains the conventional adjuvant such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and the carrier.
- the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray may be formulated, but is not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- the formulation of the present invention is the paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used as the carrier ingredient.
- the solvent, solubilizing agent or emulsifying agent can be utilized as a carrier ingredient, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-buthylglycol oil, glycerol aliphatic ester, polyethylene glycol or aliphatic ester of sorbitan, etc. can be utilized as the carrier ingredient.
- the liquid diluents such as water, ethanol or propylene glycol, suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, ortragacant, etc. can be utilized as the carrier ingredient.
- the lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be utilized as a carrier ingredient, and in particular when it is a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether can be additionally included.
- the formulation of the present invention is the surfactant-containing cleansing
- the aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulphosuccinic monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivative or ethoxylated glycerol fatty acid ester, etc. can be utilized as the carrier ingredient.
- the cosmetic composition of the present invention is the soap, cleansing formulation containing a surfactant or cleansing formulation containing no surfactant
- the soap is liquid soap, powder soap, solid soap and oil soap
- the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack
- the surfactant-free cleansing formulation is a cleansing cream, cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
- the content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15 wt%, more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
- composition comprising the Narcissus spp. plant extract of the present invention may be considred as a natural medicinal plant as a raw material. Therefore even when used as a pharmaceutical composition, food or nutraceutical composition, skin external preparation composition or cosmetic composition, side effects may be less compared to general synthetic compounds, and so it is safely included and can be usefully used.
- the present invention also refers to use of a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for controlling weight gain of a subject, preferably wherein the use is conducted as described herein. It will be understood that the definitions and preferred embodiments made in the context of the method and composition of the present invention mutatis mutandis apply to the use of the present invention.
- the use may be any use, including a cosmetic use (also: non- pharmaceutical, non-therapeutic) or a therapeutic (also: pharmaceutical) use.
- the present invention also refers to a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for use in a method of controlling weight gain of a subject, in particular wherein the subject suffers from or is at risk of a disease associated with over-weight, in particular for treating or preventing obesity or metabolic syndrome, preferably wherein the method is conducted as described herein.
- the Narcissus spp. plant extract (e.g., extract of the aerial parts of Narcissus spp. plant) which is the active ingredient of the present invention is highly safe to humans without having skin irritation and cytotoxicity, and may inhibit adipocyte differentiation, reduce the number of adipocytes, and accumulation and excessive secretion of lipids, and thus may be effectively used for a pharmaceutical composition, a food or nutraceutical composition, a skin external preparation composition and a cosmetic composition for the prevention, amelioration and treatment of obesity and/or metabolic syndrome.
- the Narcissus spp. plant extract e.g., extract of the aerial parts of Narcissus spp.
- the extract of the aerial parts of Narcissus spp. plant of the present invention may be effective in managing the adipose tissue inflammation and homeostasis in overweight context.
- the extract of the aerial parts of Narcissus spp. plant may be effective in restoring the adipose tissue homeostasis.
- FIG. 1 shows the results of measuring the effect of Narcissus spp. extracts according to the present invention on the inhibition of lipids accumulation in 3T3-L1 adipocytes.
- the results demonstrate the inhibition effect of Narcissus spp. extracts on the inhibition of the differentiation of 3T3-L1 preadipocytes into adipocytes.
- FIG. 2 shows the results of quantifying the effect of Naricissus spp. extracts according to the present invention on lipolysis of differentiated 3T3-L1 adipocytes.
- FIG. 2 demonstrates the effect of Narcissus tazetta L., Narcissus Pseudo-Narcissus L and Narcissus jonquilla L. extracts compared to caffeine. These results demonstrate the lipolytic effect of Narcissus spp. extracts.
- FIG. 3 shows the results of measuring the effect of a Narcissus tazetta L., Narcissus jonquilla L. or Narcissus Pseudo-Narcissus L extract according to the present invention on the inhibition of triglycerides accumulation in 3T3-L1 adipocytes.
- FIG. 4 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention, in comparison to the caffeine, on the release of glycerol by 3T3-L1 adipocytes.
- the results demonstrate the lipolytic effect of Narcissus jonquilla L. extract that is is stronger than caffeine.
- FIG. 5 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the release of glycerol by human fully mature adipocytes. The results confirm the lipolytic effect, as demonstrated in Fig. 4, of Narcissus jonquilla L. extract on fully mature adipocytes.
- FIG. 6 and 7 show the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the fibro-inflammation of human pre-adipocytes in inflammatory condition by quantifying IL-6 and procollagen-l releases.
- FIG. 8 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the expression of the biological markers (collagen I, Elastin, MMP-1 and MMP-9) by the immature 3T3-L1 adipocytes.
- these markers are important for the physiology and structure of the skin. It is known that these markers are also deregulated in a tissue fibrosis context such as keloids, scleroderma and hypertrophic scarring.
- FIG. 9 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the browning promoting effect in 3T3-L1 adipocytes by the stimulation of 2 mitochondrial markers UCP-1 and TFAM.
- FIG. 10 shows the results (microscopic images) of performing Oil-red 0 staining to observe the effects of a Narcissus spp. extracts (Narcissus tazetta L, Narcissus jonquilla L. or Narcissus Pseudo-Narcissus L extract) according to one embodiment of the present invention on the inhibition of the differentiation of 3T3L1 preadipocytes into adipocytes.
- A-D show cell images.
- E-F show Oil-Red 0 staining.
- a and E show control (day 0-9)
- B and F show activity of 50 pg/mL Narcissus tazetta extract
- C and G show activity of 50 pg/mL Narcissus jonquilla extract
- D and FI show activity of 50 pg/mL Narcissus Pseudo- Narcissus extract.
- the Narcissus spp. extracts obtained according to the example 1 are used for all of the experiments. It could be assumed that all of the Narcissus spp. extract obtained in the example 1 may reasonably exert the effects as described in the present disclosure.
- Example 2 Adipocyte differentiation inhibitory effect of Narcissus spp. plant extracts To evaluate the adipocyte differentiation inhibitory effect of each of the Narcissus spp. plant extracts, the following experiment was conducted.
- (immature) adipocytes (3T3-L1 ) purchased from ATCC (American Tissue Culture Collection, USA) were prepared and cultured in a DMEM medium containing 10% by weight BCS (Bovine Calf Serum).
- BCS Bovine Calf Serum
- the (immature 3T3- L1 ) adipocytes were seeded into a 6-well plate at a density of 1 x10 5 cells and then cultured in 10% by weight BCS-containing DMEM medium at 37°C under 5% CO2 until the cells reached confluence in each well.
- the cells were further cultured for 2 days and were treated with an MDI cocktail (0.5 mM isobutylmethylxanthin, 1 mM dexamethason and 1 pg/mL insulin). After 3 days, the medium was replaced with a medium containing 1 pg/mL of insulin, and after 3 days again, was replaced with a DMEM medium containing 10% by weight FBS (fetal bovine serum). From the time point when differentiation was induced by treatment with the MDI cocktail, the cells were also treated with the test sample (Narcissus spp. extracts) or caffeine, and then retreated with the same concentration of the test sample every time the culture medium was replaced. To measure the amount of lipids accumulated in the differentiated cells, the lipids were stained by Oil Red 0 staining and dissolved with isopropyl alcohol, and then the optical density at 540 nm was measured.
- an MDI cocktail 0.5 mM isobutylmethylxanthin, 1 mM dexamethason and 1
- Example 3 Lipolysis-stimulating effect of Narcissus spp. plant extract
- immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes.
- DMEM medium containing 10% by weight FBS was treated with various concentrations of the Narcissus spp. plant extracts or caffeine.
- the lipids were stained by Oil Red O staining and dissolved with isopropyl alcohol, and then the optical density at 540 nm was measured and quantified.
- Example 4 Triglyceride inhibitory effect of Narcissus spp. plant extract As described in Example 2 above, immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. Then, the amount of triglycerides produced in the cells was determined using a triglyceride determination kit (Sigma, USA).
- Example 5 Glycerol release stimulating effect of Narcissus jonquilla L. extract
- immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. Then, the release of glycerol by the cells was determined using a glycerol assay kit.
- FIG. 4 it could be confirmed that the release of glycerol in the group treated with the Narcissus jonquilla L. extract increases in a concentration-dependent manner.
- caffeine induces similar effect at highly concentration compared to the Narcissus jonquilla L extract, demonstrating the slimming benefit effect of the extract of Narcissus jonquila L. compared to caffeine.
- Example 6 Narcissus jonquilla L. extract stimulates the lipolysis of fully mature human adipocytes
- Example 7 Evaluation of the effects of the Narcissus jonquilla L. extract on fibro- inflammatory preadipocytes
- Preadipocytes were isolated from human female obese adipose tissue (39-year-old,
- Preadipocytes were cultured for 24 h in 100 mI of DMEM-10% by weight Fetal Bovine Serum (FBS) in 96-well plates.
- FBS Fetal Bovine Serum
- IBMX 3-isobutyl-1 -methylxanthine
- thiazolinedione a pro-inflammatory cocktail consisting in activated macrophage-conditioned medium (ACMC) for 14 days.
- ACMC activated macrophage-conditioned medium
- the cells were replaced in fresh DMEM/F12 medium to collect cells secretions.
- Dexamethasone 100 nM was used as anti-inflammatory response control. All conditions were performed in triplicate. The media were changed every 2 days for 14 days.
- the aforementioned model of human preadipocytes cultured in an inflammatory context, using macrophages conditioned medium (ACMC), is highly relevant, in the art, to evaluate the beneficial properties of the extract of Narcissus jonquilla L, mainly to assess its ability to reverse the deleterious effects of an inflammatory adipose tissue observed in obesity and in metabolic disorders.
- the ACMC inflammatory environment induced a high increase in procollagen-l secretion compared to the differentiation control condition.
- the dexamethasone induced a decrease in the procollagen-l secretion compared to the ACMC condition.
- the Narcissus jonquilla L. extract induced a higher decrease in the procollagen-l secretion.
- these experimental results demonstrate that the extract of Narcissus jonquilla L. can be used for counteracting or preventing the inflammation of the adipose tissue and tissue fibrosis.
- Example 8 Protective effect of Narcissus jonquilla L.
- Example 9 Browning promoting effect of Narcissus jonquilla L. extract
- immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes.
- DMEM medium containing 10% by weight FBS was treated with various concentrations of Narcissus Jonquilla extract.
- UCP-1 and TFAM real-time PCR was used for quantification of mRNA levels.
- FIG. 9 it could be confirmed that the Narcissus jonquilla L. extract upregulated the UCP-1 and TFAM mRNA expression level in the adipocytes.
- these results demonstrate the ability of Narcissus jonquilla L. extract as a slimming ingredient.
- Example 10 Test for identifying the safety of Narcissus spp. plant extract to the human skin 10 1
- Skin external formulation containing Narcissus spp. plant extract was prepared by the formulations in Table 1 below.
- Example 10-1 Each of the skin external formulations prepared in Example 10-1 above was applied every other day to the forearms of 30 healthy adults and allowed to stand for 24 hours. The test was repeated so that each subject was treated with 9 fresh patches in total, so as to confirm whether Narcissus spp. plant extract irritates the skin.
- Average response degree [[Response index X Response degree / Total number of subjects X Highest score (4 points)] X 100] / Number of examinations Regarding the response degree, 1 point was provided for ⁇ , 2 points for +, and 4 points for ++. When the average response degree was less than 3, the composition was determined to be safe for use on the skin.
- Formulation Example 1 Cosmetic formulations Formulation Example 1 -1. Preparation of skin softener
- a skin softener containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
- a nourishing cream containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
- a massage cream containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
- Table 9 The above components were mixed and then compressed to a tablet according to a conventional method.
- the above components were mixed and then filled into a gelatin capsule to a conventional method.
- Preparation Example 3-1 Preparation of Flour Food The Narcissus spp. plant extract of the present invention was added 0.5 to 5.0 parts by weight to flour, and the mixture prepared bread, the mixture prepared cakes, cookies, crackers, and noodles.
- Preparation Example 3-2 Preparation of Soup and Gravies 0.1 to 5.0 parts by weight of Narcissus spp. plant extract of the present invention were added to soup and gravies, and then meat products, noodle soup, and gravies for health promotion were prepared.
- Narcissus spp. plant extract of the present invention 5 to 10 parts by weight of Narcissus spp. plant extract of the present invention were added to milk, and various dairy products, such as butter and ice cream, were prepared using the milk
- sausage food products containing Narcissus spp. plant extract of the present invention were manufactured. Pork 65.18w%, chicken 25% by weight, starch 3.5% by weight, soybean protein 1.7% by weight, table salt 1.62% by weight, glucose 1.4% by weight, glycerin 1.5% by weight, and Narcissus spp. plant extract 0.1 % by weight of the present invention were mixed to prepare sausages according to a conventional method.
- Preparation Example 3-6 Preparation of healthy beverages
- the supplementary ingredients were homogeneously mixed with 5 g of Narcissus spp. plant extract of the present invention.
- the above supplementary ingredients are such as high fructose corn syrup (0.5% by weight), oligosaccharide (2% by weight), sugar (2% by weight), edible salt (0.5% by weight), and water (75% by weight).
- the healthy beverage was prepared by packaging in a small packaging container such as a glass bottle, plastic bottle, etc.
- Vegetable juice was prepared by adding 5 g of Narcissus spp. plant extract of the present invention to 1 ,000 ml_ of tomato or carrot juice.
- Fruit juice was prepared by adding 1 g of Narcissus spp. plant extract of the present invention to 1 ,000 ml_ of apple or grape juice.
- a pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising, as an active ingredient, at least one Narcissus spp. plant extract selected from the group consisting of a Narcissus tazetta L. extract, a Narcissus jonquilla L. extract and a Narcissus Pseudo-Narcissus L. extract.
- Narcissus spp. plant extract selected from the group consisting of a Narcissus tazetta L. extract, a Narcissus jonquilla L. extract and a Narcissus Pseudo-Narcissus L. extract.
- the pharmaceutical composition of embodiment 1 wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
- the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
- a food composition for preventing or ameliorating obesity or metabolic syndrome comprising a Narcissus spp. plant extract as an active ingredient.
- Embodiment 4 The food composition of embodiment 3, wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
- a skin external preparation composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract as an active ingredient.
- a cosmetic composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract as an active ingredient.
- Composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
- composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
- Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L., and Narcissus Pseudo-Narcissus L.
- composition according to embodiment 9 or 11 or use according to embodiment 10 or 11 wherein the aerial part is selected from the group consisting of the leaves, the stems, the flowers, or a combination of two or more thereof.
- composition according to any of embodiments 9, 11 or 12 or use according to any of embodiments 10 to 12, wherein the Narcissus spp. plant is Narcissus jonquilla L.
- composition according to any of embodiments 9, 11 to 13 or use according to any of embodiments 10 to 13, wherein the at least one extract of the aerial parts of Narcissus spp. is characterized in that:
- composition according to any of embodiments 9, 11 to 14 or use according to any of embodiments 10 to 14, wherein the alcohol is selected from the group consisting of ethanol, methanol, propanol, butanol, pentanol, phenol, glycerol, 1,3-butylene glycol, propane diol, or a mixture of two or more thereof.
- composition according to any of embodiments 9, 11 to 15 or use according to any of embodiments 10 to 15, wherein the composition comprises 0.0001 to 15% by weight, preferably 0.001 to 15% by weight, more preferably 0.001 to 10% by weight, based on the total weight of the composition.
- a cosmetic or pharmaceutical composition comprising: a. at least one extract of the aerial parts of Narcissus spp. as defined in any one of embodiments 9 to 16 as an active slimming ingredient; and b. at least one further cosmetically and/or pharmaceutically acceptable ingredient other than the extract of Narcissus spp., preferably wherein the composition is a composition for topic use selected from the group consisting of a solution, a suspension, an emulsion, a cream, a paste, a gel, a lotion, a powder, a microcapsule, a microgranule, a soap, a surfactant-containing water, an oil, an ointment, and a spray, or wherein the composition is a food or a nutraceutical composition which is administered orally.
- the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
- Cosmetic use of a composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
- the cosmetic use comprises: - preventing the lipid accumulation by regulating the adipocyte differentiation, inhibiting excessive secretion of adipocyte-derived lipids, stimulating adipocytes lipolysis, promoting the conversion of white adipocytes into brown adipocytes by increasing the expression of UCP-1 and/or TFAM, controlling the structure of the dermal extracellular matrix by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin, counteracting or preventing the tissue fibrosis by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin; counteracting or preventing the inflammation of the adipose tissue by inhibiting the secretion of IL-6, counteracting or preventing the inflammation-induced ectopic collagen I depots formation in the adipose tissue by inhibiting the synthesis of procollagen-l; controlling the secretion of adipokines from adipose tissue, and a combination of
- the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo-Narcissus L, preferably Narcissus jonquilla L
- the aerial part is selected from the leaves, the stems, the flowers, or a combination of two or more thereof, preferably the stems and flowers;
- a cosmetic method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient as defined in any of the embodiments 9 to 17.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Botany (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject. Furthermore, the present invention refers to the use of such composition for controlling weight gain of a subject and to such composition for use in a method for of controlling weight gain of a subject.
Description
COMPOSITIONS COMPRISING NARCISSUS SPP. PLANT EXTRACT AND USE THEREOF
Technical field The present invention relates to a method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject. Furthermore, the present invention refers to the use of such composition for controlling weight gain of a subject and to such composition for use in a method for of controlling weight gain of a subject.
The present invention further relates to com postions comprising Narcissus spp. plant extract and use thereof. It further relates to compositions for preventing and/or treating obesity and/or metabolic syndrome comprising Narcissus spp. plant extract. Moreover, the present invention relates to compositions for preventing and/or treating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract. The Narcissus spp. plant extract, which is the active ingredient of the present invention, may inhibit an increase in the number of adipocytes and lipid accumulation by inhibiting adipocyte differentiation, inhibit excessive secretion of adipocyte-derived lipids, is a safe substance having no skin irritation and cytotoxicity, and is useful for a pharmaceutical composition, a food composition, a skin external preparation composition and a cosmetic composition for the prevention, amelioration and treatment of obesity, metabolic syndrome and, more generally for improving the overall skin properties.
Background of the invention
Worldwide, obesity has increased rapidly and is known to be a significant cause of chronic diseases such as hypertension, hyperlipidemia, and diabetes. The World Health Organization has defined obesity as a 21st century epidemic/pandemic, and the prevalence of obesity in the world more than doubled between 1980 and 2014. Although the mortality rate from obesity has increased worldwide, obesity is preventable (WHO, 2014). In Korea, 32.5% of adults are obese, and 2 out of 5 adult men and 1 out of 4 adult women are obese, which is a serious problem that threatens national health (Health and Nutrition Examination Survey, 2014).
Obesity refers to a phenomenon in which excess calories are accumulated as fats in the body by ingesting more calories than the calories consumed. The World Health Organization (WHO) reported that about 400 million people in the world over the age of 15 are classified as obese, and 1.6 billion people are overweight (September 2006). In line with this trend, obesity has emerged as a severe social problem, not just an individual disease. Obesity is known to be caused by genetic factors, environmeltal and/or lifestyle factors resulting from westernized dietary habits, and psychological factors resulting from stress, but the exact cause or mechanism of obesity has not been clearly identified.
The goals of obesity treatment are broadly divided into two. One goal is to lose weight by burning excess fat, and a further goal is to improve metabolic imbalance. Abdominal obesity is closely related to symptoms such as insulin resistance, type 2 diabetes, hypertension, and lipid metabolism, and acts as a strong risk factor for early arteriosclerosis, ischemic heart disease, and cerebrovascular disease (Kopleman P.G., Nature, 404, 2000; Manson et al., New England J. Med., 333, 1995; Must et al., JAMA,
282, 1999). Thus, currently, the treatment of obesity aims not only at losing weight but also at ameliorating metabolic abnormalities by early eliminating factors that cause cardiovascular disease. Studies focused on suppressing obesity by controlling dietary intake control and energy consumption have also been actively conducted. Hypothalamus, motor nervous, autonomic nervous, and peripheral nervous systems are all involved in regulating food intake behaviors, and the central nervous system, especially the hypothalamus, plays an important role in the etiology of obesity. Typical factors secreted from the hypothalamus include neuropeptide Y, POMC/CART, melanocortin receptor, norepinephrine, serotonin, and the like. Current strategies for developing obesity therapeutic agents include reducing food intake, inhibiting calorie absorption, promoting exothermic reactions, regulating energy metabolism, and regulating signal transduction through the nervous system (Mi-Jung Park, Korean J Pediatr 48(2), 2005).
Among obesity therapeutic drugs known to date, the most representative drugs include Xenical™ (Roche Pharmaceuticals, Switzerland), Reductil™ (Abbott, USA), Exolise™ (Arkopharma, France), and the like, but cause adverse effects such as cardiac diseases, respiratory diseases, neurological diseases and the like. The persistence of efficacy thereof is low. Accordingly, the search for safer and more effective anti-obesity substances is ongoing.
Caffeine is a well known slimming ingredient (also designatable as slimming agent) which can be incorporated in many formulation forms such as topical, nutraceutical compositions. Precisely, caffeine is an alkaloid, enables to prevent the excessive accumulation of fat in adipose tissue, to stimulate the lipolysis, to degrade triglycerides and, thus, it takes part in the reduction of fat-related skin damages such as cellulitis for example.
Fat stored in adipocytes is used as an important energy source in the body, but as obesity progresses, the number of adipocytes increases and adipocytes differentiate. As adipocytes differentiate, the synthesis of triglycerides increases. It is known that triglycerides accumulated and stored in adipocytes increase the size of adipocytes, and the diameter of adipocytes may increase about 20 times due to the storage of fat therein, and as a result, the cell volume increases several thousand times. This size of adipocytes may be controlled by dietary control, but the process in which new preadipocytes differentiate into adipocytes is not effectively controlled by dietary control. Thus, for the fundamental treatment or inhibition of obesity, it is important to control the adipocyte differentiation process of adipocytes.
Another way to tackle obesity, is to stimulate the “browning” of white adipose tissue (WAT). In contrary to white adipose tissue, the brown adipose tissue (only present in the first few months of human life) contain cells with smaller fat droplets and are more energetically active due to their greater number of mitochondria. Brown adipocytes express a protein called uncoupling protein 1 (UCP-1 ) localized to the mitochondria membranes where it short-circuits the pathway to produce energy. This energy is then dissipated for heat production in response to cold. Thereby, heat is produced while energy is consumed which eventually leads to the elimination of fat deposits. Thus, activating the browing of white adipose tissue through the stimulation of UCP-1 expression would lead to an increase in fat burning without additional exercise. Interestingly, an adipose tissue similar to brown adipose tissue can be seen in adults when they are subjected to low temperatures and exercise. This brown adipose tissue-like is called “beige adipose” tissue. Beige fat arises from white fat (precursors or mature cells). Despite this common origin, beige fat is
thermogenic, like brown fat, so it plays a different metabolic role than white fat. The term “browning” describes the emergence of beige adipocytes in WAT, a reversible process that represents adaptation to increased thermogenic demand and exercise.Thanks to the plasticity of the adipose tissue, improving obesity state may be expected.
Moreover, the expansion of adipose tissue in obesity is accompanied by the accumulation of immune cells that contribute to a state of chronic inflammation and dysregulated metabolism such as the insuline resistance, the impairment of adipocyte function. Adipose tissue macrophages represent the most abundant class of immune cells in adipose tissue and are involved in the regulation of several regulatory physiological processes, such as tissue remodeling and insulin sensitivity. It has been shown that macrophages recruited from blood monocytes are critical components of the generation of adipose tissue inflammation, but their proliferation plays a role in the early stages of obesity and in sustaining adipose tissue inflammation (Russo and Lumeng, Immunology 2018).
Consequently, a disproportionately increase of pro-inflammatory macrophages in WAT is associated with obesity and compromises the adipose tissue homeostasis by promoting the adipocyte hypertrophy, the altered secretion profile of adipocytes, the metabolic dysfunction and the excessive deposition of collagen fibers around adipocytes, so called peri-adipocyte fibrosis, which reinforce the macrophage increase in adipose tissue and perpetuate a vicious cycle with the maintenance of fibro-inflammation in adipose tissue of an obese or an overweight person. Additionally, it is also known that the adipose tissue of obese or an overweight person is mainly constituted by enlarged adipocytes. It has been reported that adipocyte enlargement was significantly decreases the dermal elasticity (Ezure et al., Experimental dermatology, DO1 10.1111 ; 2015).
More generally, it has been shown that obesity is an aggravating factor for skin properties (Mori et al., Lipids in Health Disease, DO1 10.1186; 2017). Indeed, the authors showed a reduction of the moisturizing and barrier functions of the skin, and an inflammation-like symptom including redness and roughness. However, adipocytes contribute to various skin functions and their ability to perform many of their functions is influenced by their stored lipids. Indeed, it is agreed that dermal fibrosis involves the deposition of excessive extracellular matrix and the loss of adipocytes.
Meanwhile, Narcissus spp. plants are perennial plants belonging to the Narcissus family and are collectively referred to as narcissus. Narcissus is planted as bulbs in winter and blooms mainly in spring. Bulbs of narcissus are toxic and are used as a disinfectant for boils or swelling, flowers thereof are used to produce perfumed oil, and scaly stems thereof are used as a therapeutic agent as an expectorant of whooping cough. It has been reported that microniosomes, including narcissus bulbs, exhibit a wound healing effect by promoting the proliferation and migration of fibroblasts (Ramaesh M et al., Daru 2018 Sep 12. DOI: 10.1007/s40199-018-0211 -7) and have an anticancer effect (Rezadoost MH et al. , Mol Biol Rep. 201946(5):5131-5142). In addition, KR-A 10-2016-0114794 discloses that a narcissus bulb extract has the effects of improving skin elasticity, reducing wrinkles, and reducing skin irritation, and KR-B 10-1807978 discloses a composition containing a Narcissus spp.-derived peptide that activates Sirt6. However, the adipocyte differentiation regulatory effect suggested by the present invention has not yet been reported.
Therefore, there is still a need to provide an extract of Naricissus spp. plant capable to exert, not only, a slimming effect, but also to regulate the impaired metabolic and endocrine
functions of the adipose tissue, and thus, more generally a product capable to improve the overall skin properties, particularly its physiology and its aspect. Accordingly, the present inventors have made efforts to find a natural product-derived substance that has excellent anti-obesity, anti-fat effects, an homeostasis regulating effect on adipose tissue, without having side effects, and as a result, have found that a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) exhibits an excellent anti-obesity effect, for example, by controlling the number of produced adipocytes through the regulation of adipocyte differentiation and releasing excess energy accumulated, thereby completing the improvement of the overall skin properties.
Summary of the invention
Surprisignly, it has been found that an extract of the aerial parts of Narcissus spp. plant can be used as a slimming ingredient. Further, it has surprisignly been found that a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant can be used for preventing and/or treating obesity, for preventing and/or treating fat-related disorders in adipose tissue, for preventing and/or alleviating or treating the fat-related skin disorders or damages. Hence, the at least one extract of the aerial parts of Narcissus spp. plant is useful to comply with the improvement of the overall skin properties.
Accordingly, an aspect of the present invention is a method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject.
The method may be any method, including a cosmetic method (also: non-pharmaceutical,
non-therapeutic) or a therapeutic (also: pharmaceutical) method.
One object of the present invention is to provide a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient. Thus, in a preferred embodiment, the extract of aerial parts of a Narcissus spp. is an active slimming ingredient.
Another object of the present invention is to provide a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant for use for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages seleted from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight- related skin.
Another object of the present invention relates to a cosmetic use of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for treating or alleviating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
Another object of the present invention is to provide a pharmaceutical composition for preventing and/or treating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract (e.g.,an extract of the aerial parts of Narcissus spp. plant). In an embodiemnt of the present invention, the method is a method of preventing, ameliorating, or treating
obesity and/or metabolic syndrome.
Another object of the present invention is to provide a skin external preparation composition for preventing and/or treating obesity comprising a Narcissus spp. plant extract.
Still another object of the present invention is to provide a food composition for preventing or ameliorating obesity and/or metabolic syndrome comprising a Narcissus spp. plant extract.
Yet another object of the present invention is to provide a cosmetic composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant).
Still another object of the present invention is to provide a food or nutraceutical composition comprising (or consisting of) an extract of the aerial parts of Narcissus spp. plant for preventing or ameliorating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for preventing or ameliorating metabolic syndrome.
A further object of the present invention is to provide a cosmetic method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema and striae, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of
Narcissus spp. plant as an active slimming ingredient.
Still yet another object of the present invention is to provide a method of preventing, ameliorating, or treating obesity and/or metabolic syndrome using a composition comprising (or consisting of) a Narcissus spp. plant extract.
Detailed description of the invention
The present invention relates to compositions for preventing, ameliorating, and treating obesity or fat-related disorders and/or metabolic syndrome comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition, a skin external preparation composition, a cosmetic composition and a food (or nutraceutical) composition, which each comprise a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) as an active ingredient. The compositions are highly safe for humans without having skin irritation and cytotoxicity, and may inhibit adipocyte differentiation, reduce the number of adipocytes, and may effectively inhibit lipid accumulation and excessive secretion of adipocyte-derived lipids. In addition, the compositions enable to regulate the impaired metabolic and endocrine functions of the adipose tissue. It will be understood that, in a composition consisting of Narcissus spp., the composition is the extract.
An aspect of the present invention relates to a composition comprising (or consisting of) at least one Narcissus spp. plant extract (e.g., extract of the aerial parts of Narcissus spp. plant) as an active slimming ingredient.
An aspect of the present invention provides a pharmaceutical composition for preventing and/or treating obesity or metabolic syndrome comprising at least one extract of a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant).
According to an embodiment of the invention, the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo- Narcissus L. In a preferred embodiment of the invention, the Narcissus spp. plant is Narcissus jonquilla L.
As used herein, the term "extract" refers to products such as liquid products obtained by immersing materials including plants in various solvents, and then performing extraction and fractionation in a room temperature or elevated temperature state for a predetermined time, or solid products obtained by removing the solvents from the liquid products. In addition to the above-described products, the term “extract” may be interpreted as including all dilutions of the products, concentrates thereof, crude products thereof, and purified products thereof.
In the present invention, the “Narcissus spp. plant extract” is obtained by extraction from the leaf, flower, stem, root and the like of the Narcissus spp. plant, preferably the flower, leaf, and stem of the Narcissus spp. plant. Prefreably, it is at least one part of the aerial part of the Narcissus spp. plant. Preferably, the “Narcissus spp. plant extract” is obtained by extraction from the aerial parts of the Narcissus spp. plant, preferably from the leaf, flower, stem and the like of the Narcissus spp. plant.
According to an embodiment of the present invention, the aerial part of the Narcissus spp.
plant may be selected from the leaves, the stems, the flowers, or a combination of two or more thereof. Preferably, the aerial part of the Narcissus spp. plant comprises stems and/or flowers.
In an embodiment of the present invention, the aerial part of Narcissus spp. is characterized in that:
(i) it is an aqueous, a hydroalcoholic, or an alcoholic extract; and/or
(ii) it comprises at least 0.05% by weight (also “wt%), preferably at least 0.1 % by weight, more preferably at least 0.15% by weight, particularly at least 0.2% by weight of dry matter, referred to the total weight of the extract.
In the present invention, the Narcissus spp. plant extract may be obtained by extraction with water or any organic solvent. At this time, the organic solvent may preferably be water, a polar solvent, or a non-polar solvent, but the solvent is not limited thereto as long as an extract having the effects of inhibiting adipocyte differentiation, inhibiting lipid accumulation of adipocytes and excessive secretion of adipocyte-derived lipids, restoring the adipose tissue homeostasis, alleviating the overweight skin damages and promoting the firmness of the overweight-related skin may be obtained.
In this context, an alcohol contained in a hydroalcoholic or alcoholic extract may be any alcohol. Preferably, an alcohol contained in a hydroalcoholic or alcoholic extract is selected from the group consisting of ethanol, methanol, propanol, butanol, pentanol, phenol, glycerol, 1 ,3-butylene glycol, propane diol, or a mixture of two or more thereof, in partilcar wherein an alcohol contained in a hydroalcoholic or alcoholic extract is ethanol;
At this time, the organic solvent may preferably be water, a polar solvent, or a non-polar solvent, but the solvent is not limited thereto as long as an extract having the effects in the spirit of the disclosure of the present invention may be obtained. More preferably, the solvent may be water, C1-C4 lower alcohol (e.g., selected from ethanol, methanol, propanol, butanol), pentanol, phenol, glycerol, 1 ,3-butylene glycol, propane diol or a mixture of two or more thereof. Preferably, the solvent may be a mixture of water and ethanol or a mixture of water and methanol. More preferably, the solvent may be an alcohol selected from methanol and ethanol. Optionally, the solvent may be a mixture of water and ethanol.
In a preferred embodiemnt, the at least one extract of aerial parts of Narcissus spp. is an aqueous extract which is obtained by extracting the aerial parts of Narcissus spp. with hot water of a temperature of 25 to 200°C, of 50 to 175°C, of 60 to 150°C, of 70 to 140°C, of 80 to 130°C, or of 90 to 120°C.
For instance, the temperature used in this context may in the range of 50 to 70°C, of 60 to 90°C, of 90 to 100°C, of 100 to 110°C, of 110 to 120°C, or of 100 to 150°C.
In a preferred embodiment, extracting the aerial parts of Narcissus spp. with hot water (also designatable as “the hot water extraction) is conducted under reflux.
Such extraction under reflux may be conducted 1 time (i.e., once), 2 times (i.e., twice),
3 times, 4 times, 5 times, or more that 5 times. The expression “times” in this context may also be designated as “in extraction cycles” In a preferred embodiment, extracting the aerial parts of Narcissus spp. with hot water is conducted 1 time, 2 times or 3 times, in particular
3 times.
Extraction under reflux may be conducted for a time sufficient for extraction. For instance, one extraction (cycle) may be conducted for a time range of from 1 min to 24 h, of from 5 min to 12 h, of from 10 min to 6 h, of from 15 min to 3 h, of from 15 min to 1 h, or of from 15 min to 45 h, or of from 20 min to 35 h. The total time for extraction may be performed within 5 min to 24 h, of from 10 min to 12 h, of from 15 min to 12 h, of from 30 min to 6 h, of from 90 min to 5 h, of from 2 h to 4 h, of from 2 h to 3 h.
In a preferred embodiment, extracting the aerial parts of Narcissus spp. with hot water is conducted at 90 to 120°C, 3 times under reflux, wherein each reflux may last 20 to 35 min, and the procedure optionally is conducted during 2 hours.
In addition, a method for obtaining the extract is not particularly limited as long as it may provide an extract having the effects of inhibiting adipocyte differentiation and inhibiting lipid accumulation of adipocytes or excessive secretion of adipocyte-derived lipids, restoring the adipose tissue homeostasis, alleviating the overweight skin damages and promoting the firmness of the overweight-related skin. In addition, a method for obtaining the extract is not particularly limited as long as it may provide an extract having the effects in the spirit of the disclosure of the present invention. Examples of the extraction method may include hot water extraction, cold water extraction, ultrasonic extraction, and reflux cooling extraction methods. Extraction may preferably be performed by the ultrasonic extraction method.
The ultrasonic extraction is a method of extracting useful components from various natural materials at room temperature by a physical force rather than chemical force using a vibrating element having a vibration frequency of 20,000 times or more per second. Unlike
solvent extraction, vegetable oil extraction, or steam distillation extraction, the ultrasonic extraction has the advantage of being able to extract high concentrations of active ingredients from natural materials at room temperature without destroying the active ingredients.
In one exemplary embodiment, the ultrasonic extraction may be performed on the dried powder of the aerial part of a Narcissus spp. plant using a 60% to 80% (by volume) ethanol solution at room temperature for 24 to 72 hours. Preferably, the ultrasonic extraction may be performed using a 50% to 90% (by volume), preferably a 65% to 75% (by volume) ethanol solution at room temperature for 36 to 60 hours. More preferably, the ultrasonic extraction is performed using a 60 to 80% (by volume), preferably 70% ethanol solution at room temperature for 20 to 50 hours, preferably for 25 to 45 hours, more preferably for 40 hours. In one embodiment, if the ethanol concentration and the extraction time are lower than the lower limits of the above-described ranges, the active ingredient of the present invention, contained in the aerial part of the Narcissus spp. plant, will not be sufficiently extracted. If the ethanol concentration and the extraction time are higher than the upper limits of the above-described ranges, there will be no significant difference in the amount of the active ingredient extracted, impurities will be extracted in addition to the active ingredient, and the efficiency of the extraction process will be reduced.
In another specific embodiment, the hot-water extract is performed on the dried powder of the aerial parts of the Narcissus spp. plant in purified water at high temperature, preferably 100 to 150°C, more preferably 100 to 130°C, even more preferably 110 to 130°C, most preferably 121 °C, for 20 minutes to 1 hour, preferably 20 minutes to 50 minutes, more preferably 20 minutes to 40 minutes, most preferably 30 minutes.
The obtained Narcissus spp. plant extract may be concentrated under reduced pressure using, but not limited to, a vacuum concentrator or a rotary vacuum evaporator. In addition, after vacuum concentration, the extract may be dried through, but not limited to, freeze drying, reduced-pressure, vacuum drying, boiling drying, or spray drying. As used herein, the term “dry extract’ may be understood in the broadest sense as a dry matter (physical form) without the solvent.
As used herein, the expression “adipose tissue homeostasis” means that the adipose tissue having its normal or healthy state in terms of cell proliferation, cell death, and its metabolic function.
As used herein, the term “cellulites” also known as “orange peel”, is characterized by an uneven skin profile affecting the tissue around the thighs, buttocks and hips, the areas where adipose tissue is deposited in the largest amounts in a subject. The dimply appearance is caused by the extension of the fat tissue into the fibrous connective tissue. Larger fat deposits exacerbate this problem as the pressure from the fat onto the connective tissue increases. As used herein, the term “striae or striae distensae”, also known as stretch-marks, is a skin defect caused by excessive stretching of the skin in areas with large amounts of adipose fat tissue, such as the breasts, buttocks, abdomen, hips, thighs and underams. They appear first as erythematous linear bands, which turn purple and then white overtime, becoming atrophic and depressed. Overweight, particularly obesity is one of the fastest
bringers of striae as it involves rapid growth which the skin is less likely to keep up this evolution.
The Narcissus spp. plant extract which is an active ingredient of the present invention has the general beneficial effects of restoring or promoting the adipose tissue homeostasis, treating or alleviating the overweight-induced skin damages, particularly by controlling adipogenesis by inhibiting adipocyte differentiation, reducing the number of (mature) adipocytes, inhibiting the accumulation and excessive secretion of (adipocyte-related) lipids, promoting lipolysis of adipocytes, by promoting the conversion of white adipocytes into brown adipocytes, by controlling the structure of the dermal extracellular matrix, by counteracting the inflammation of the adipose tissue and by controlling the secretion of adipokines. Indeed, by achieving the aforementioned activities and functions, the extract of the aerial parts of Narcissus spp. according to the present invention can be used as an ingredient to comply with the slimming purposes, more generally to improve the overall skin properties, particularly its physiology and aspect. In one specific example, it was confirmed that an ethanol extract of an aerial part of a Narcissus spp. plant has the effects of inhibiting an increase in the number of adipocytes by inhibition of adipocyte differentiation and inhibiting lipid accumulation and secretion by inhibiting the production of adipocyte-derived lipids (FIGS. 1 and 10). Therefore, the composition comprising the Narcissus spp. plant extract according to the present invention is effective in inhibiting adipocyte differentiation, inhibiting accumulation of adipocyte-derived lipids, and inhibiting excessive secretion of adipocyte-derived lipids, and thus is useful for the prevention, amelioration and treatment of obesity and metabolic syndrome.
As used herein, the term "obesity" refers to a condition in which the number of adipocytes
is above average and lipids are excessively accumulated in adipocytes.
As used herein, the term "metabolic syndrome" refers to a disease caused by obesity or at least over-weight, or at least having a high correlation with them (e.g. obesity). For example, the metabolic syndrome may be, but is not necessarily limited to, any one selected from among fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome. The lipid-related metabolic syndrome refers to a disease in which various metabolic syndromes such as diabetes and obesity appear simultaneously in a single person.
In the present invention, "ameliorating obesity" refers to suppress, reduce, and eliminate the increase in the number of adipocytes and excessive accumulation of lipids in adipocytes due to excessive adipocyte differentiation in a subject.
In the present invention, "ameliorating metabolic syndrome" refers to suppress, reduce, and eliminate metabolic syndrome caused by an increase in the number of adipocytes and excessive accumulation of lipids in adipocytes due to excessive adipocyte differentiation in a subject.
As used herein, the term “overweight-related skin damages” refers to the damages caused by the over fat-accumulation within the adipose tissue. For example, such damages may include cellulitis, striae, lymphedema, sagginess or softening and tissue fibrosis selected from keloids, scleroderma and hypertrophic scarring. In the context of the invention, the term “fat” and “lipid” have the same meaning and may be understood interchangeably.
As used herein, “treating or alleviating the overweight-related skin damages” refers to suppress, reduce or eliminate the aforementioned overweight-related skin damages.
As used herein in teh context of gene regulation, the term “controlling or regulating” refers to the upregulation and/or downregulation of the expression of at least one gene.
The content of the Narcissus spp. plant extract (e.g., the extract of the aerial parts of Narcissus spp. Plant), which is contained in the above composition, may be, but is not specifically limited to, an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15% by weight, and more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
A further aspect of the invention relates to a cosmetic or pharmaceutical composition comprising: a. at least one extract of the aerial parts of Narcissus spp. of as defined above (e.g. , as an active slimming ingredient); and b. at least one further cosmetically and/or pharmaceutically acceptable ingredient other than the extract of Narcissus spp., preferably wherein the composition is a composition for topic use selected from the forms selected from the group consisting of a solution, a suspension, an emulsion, a cream, a paste, a gel, a lotion, a powder, a microcapsule, a microgranule, a soap, a surfactant- containing water, an oil, an ointment, and a spray, or wherein the composition is a food or a nutraceutical composition which is administered orally.
Another aspect of the present invention relates to a method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight- induced skin damages selected cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient as defined above.
It will be understood that the definitions and preferred embodiments made in the context of the method and composition of the present invention mutatis mutandis apply to the cosmetic method of the present invention.
Another aspect of the invention relates to a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant for use for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
In an embodiment of the present invention, the composition (pharmaceutical) is for use for preventing and/or treating a metabolic syndrome selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid- related metabolic syndrome.
It will be understood that the definitions and preferred embodiments made in the context of the methoid and composition of the present invention mutatis mutandis apply to the use of
the composition or to the composition for use of the present invention.
Accordingly, in a preferred embodiemnt, the method of the present invention is:
(a) for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin; and/or
(b) for preventing and/or treating a metabolic syndrome, in particular wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid- related metabolic syndrome.
Another aspect of the invention relates to a cosmetic use of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
In an embodiment of the invention, the cosmetic use comprises: preventing the lipid accumulation by regulating the adipocyte differentiation, inhibiting excessive secretion of adipocyte-derived lipids, stimulating adipocytes lipolysis, promoting the conversion of white adipocytes into brown adipocytes by increasing the expression of UCP-1 and/or TFAM,
controlling the structure of the dermal extracellular matrix by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin, counteracting or preventing the tissue fibrosis by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin; counteracting or preventing the inflammation of the adipose tissue by inhibiting the secretion of IL-6, counteracting or preventing the inflammation-induced ectopic collagen-l depots formation in the adipose tissue by inhibiting the synthesis of procollagen-l by preadipocytes, controlling the secretion of adipokines from adipose tissue, and a combination of two or more thereof.
In an embodiment, the cosmetic use of the composition of the invention is characterized in that:
A. the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo-Narcissus L, preferably Narcissus jonquilla L
B. the aerial part is selected from the group consisting of the leaves, the stems, the flowers, or a combination of two or more thereof, preferably the stems and the flowers;
C. it is an aqueous, a hydroalcoholic, or an alcoholic extract, preferably an alcoholic extract, more preferably an ethanolic extract; and/or
D. the use is as defined above.
As used herein, the term "pharmaceutical composition" means a composition prepared for
preventing and/or treating disease and may be formulated into various forms according to each conventional method. For example, the composition may be formulated into oral dosage forms such as discutient, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., and parenteral dosage forms such as diluents or excipients such as lubricants, wetting agents, flavoring agents, emulsifying agents, suspending agents, preservatives, surfactants, etc. In addition, it can be formulated and used in the form of external preparations, suppositories, skin external preparations, and sterile injectable solutions. As a specific example, the composition of the present invention may be used orally in an oral dosage form. As another specific example, the composition of the present invention may be used by a method such as direct application or dispersion to a area such as a thigh, buttocks, or abdomen where a large number of adipocyte are distributed. The above application and dispersion are not limited to the above area and may be applied to any area in which adipocytes are developed.
In addition, according to each formulation, a pharmaceutically acceptable carrier, such as a buffering agent, a painless agent, a solubilizing agent, an isotonic agent, a stabilizer, a base agent, and the like, may be prepared by additionally including a carrier known in the art.
As used herein, the term “pharmaceutically acceptable carrier” may refer to a carrier or a diluent that does not interfere with the biological activity and properties of an active ingredient to be injected without stimulating organisms. The type of carrier which can be used in the present invention is not particularly limited, and any pharmaceutically acceptable carrier commonly used in the art may be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, etc. These may be used
alone or in combination with two or more thereof. The carrier may include a non-naturally occurring carrier.
The composition of the present invention may be administered in a pharmacologically effective amount. The above pharmacologically effective amount refers to an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects. Effective dosage levels depend on the patient's health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used in combination or concurrently, and other factors well known in the medical field. Specifically, it is generally 0.01 mg to 5000 mg per 1 kg of the body weight of the administered subject and may be dividedly administered once a day or several times a day at predetermined time intervals according to the judgment of a doctor or pharmacist, but is not limited thereto.
In addition, the pharmaceutical composition of the present invention may be used alone or in combination with other pharmaceutically active compounds exhibiting a prophylactic or therapeutic effect of obesity and/or metabolic diseases (equivalent designatable as disorders) or in an appropriate set.
The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It is important to administer an amount that can achieve the maximum effect in a minimum amount without causing side effects by taking all of these factors into consideration, and it
can be easily decided by a person skilled in the art.
For example, but not limited thereto, in addition to the pharmaceutical composition comprising a Narcissus spp. plant extract (e.g., an extract of the aerial parts of Narcissus spp. plant) of the present invention as an active ingredient, it can be used in combination with commonly used antiobestic agent such as locasein that acts on the central nervous system to reduce appetite through activation of the central nervous system to suppress appetite, orlistat that inhibits fat absorption as an antiobestic agent of non-central nervous system, and Liraglutide that is an analogue of GLP-1 (Glucagon-Like Peptide 1 ) as an appetite control substance, and like.
As used herein, the term “administration” refers to introducing the pharmaceutical composition of the present invention to a subject in any suitable manner, and the injection route of the composition of the present invention may be administered via oral or parenteral various routes as long as it can reach the desired tissue.
The method of administration of the pharmaceutical composition according to the present invention is not particularly limited thereto, and may be in accordance with a method commonly used in the art. As a non-limiting example of the administration method, the composition may be administered orally or parenterally. Specifically, the composition of the present invention may be used by a method such as direct application or dispersion to a area such as a thigh, buttocks, or abdomen where a large number of adipocytes are distributed.
The pharmaceutical composition according to the present invention can be prepared in
various formulations according to the intended administration method.
The frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or several times by dividing the dose.
In another aspect, the present invention provides a method for preventing and/or treating lipid-related diseases (equivalent designatable as disorders) comprising administering a pharmaceutical composition containing a Narcissus spp. plant extract (e.g., an extract of the aerial parts of the Narcissus spp. plant) to a subject.
The Narcissus spp. plant extract and its preventive and therapeutic effects on obesity and metabolic diseases (equivalent designatable as disorders) are as described above.
As used herein, the term "subject" may mean all animals including humans who have or are likely to develop obesity and/or metabolic diseases (equivalent designatable as disorders). The animals may be mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. in need of treatment for symptoms similar to humans, but are not limited thereto. Humans are preferred. A subject in the context of the present invention may be of any age. For instance, a subject may be an adult, an adolescent, or a child, preferably an adult.
The term “controlling weight gain” may be understood in the broadest sense as having an influence on body weight and increase in weight. Preferably, controlling weight gain is reducing weight gain. In one embodiment, controlling weight gain is minimizing or
(essentially) preventing weight gain. In one embodiment, controlling weight gain is reducing weight of the subject of interest. In one embodiment, controlling weight gain is having a slimming effect (i.e., serving as an active slimming ingredient). In one embodiment, controlling weight gain is preventing, ameliorating, or treating obesity and/or metabolic syndrome, and/or restoring the adipose tissue homeostasis, and/or alleviating the overweight skin damages and/or promoting the firmness of the overweight-related skin may be obtained.
The prevention and/or treatment method of the present invention may specifically include administering the composition in a pharmaceutically effective amount to a subject who has or is at risk of developing obesity and/or metabolic disease. The administration method is as described above.
The prevention may refer to any action of inhibiting or delaying the onset of obesity and/or metabolic diseases (e.g., syndrome and metabolic disorders of the adipose tissue, the overweight-related skin damages), by administering the composition for preventing and/or treating obesity and/or metabolic diseases (equivalent designatable as disorders) according to the present invention to a subject.
In addition, the treatment may refer to any action of improving or benefitting the symptoms of obesity and/or metabolic diseases (e.g., syndrome and metabolic disorders of the adipose tissue and/or the overweight-related skin damages) by administering the composition of the present invention to a subject suspected of developing obesity and/or metabolic disease.
The pharmaceutical composition comprising the Narcissus spp. plant extracts is as described above.
The composition of the present invention may contain a pharmaceutically acceptable carrier, excipient or diluent in addition to the above-described active ingredients for administration. The carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl Cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
A suitable dosage of the composition of the present invention may vary depending on the condition and weight of the patient, the severity of the disease, the form of the drug, and the time, but may be appropriately selected by a person skilled in the art. Specifically, the dosage of the Narcissus spp. plant extracts may be 50 to 500 mg/Kg.
In another embodiment, the present invention provides a skin external preparation for preventing or ameliorating obesity comprising the Narcissus spp. plant extract.
The Narcissus spp. plant extract and its preventive and therapeutic effects on obesity are as described above.
The skin external preparation of the present invention can be used for the purpose of preventing and ameliorating obesity, and the skin external preparation can be generally used for areas such as thighs and buttocks in which cellulite formed by excessive
adipocyte differentiation and accumulation of lipids in adipocyte is excessively distributed. It can be applied to any area in which adipocytes are developed, not limited to the above area.
The skin external preparation according to the present invention may be formulated by containing a medium or base that is acceptable cosmetically or dermatologically. These are all formulations suitable for topical application, such as solutions, gels, solids, dough anhydrous products, emulsions obtained by dispersing the oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules, the form of ionic (liposomes) and nonionic vesicle dispersant, or the form of a cream, skin, lotion, powder, ointment, spray, pack or conceal stick. It may be used in the form of a foam or an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.
In addition, the skin external preparation according to the present invention includes fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic Or nonionic emulsifiers, fillers, sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles, or adjuvants commonly used in the field of cosmetics or dermatology as any other ingredients commonly used in cosmetics. The adjuvant is introduced in an amount generally used in the field of cosmetology or dermatology.
The content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight,
preferably 0.0001 to 15 wt%, and more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
In another embodiment, the present invention provides a food or nutraceutical composition for preventing or ameliorating obesity and/or metabolic syndrome comprising the Narcissus spp. plant extract.
The Narcissus spp. plant extract and its preventive and therapeutic effects on obesity and metabolic syndrome are as described above.
When the composition of the present invention is used as a food additive, the Narcissus spp. plant extracts may be added as it is or may be used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment) and may further include food additives acceptable for food. Since the composition of the present invention uses an extract derived from a natural product as an active ingredient, there is no problem in terms of stability, so there is no significant limitation on the amount of mixing.
The food or nutraceutic composition of the present invention may include all foods in a conventional sense and may be mixed with terms known in the art, such as functional foods and health functional foods.
As used herein, the term 'functional food" refers to a food manufactured and processed using raw materials or ingredients having functions useful for the human body according to
the (Korean) Health Functional Food Act No. 6727, and the term "functional" refers to ingestion for the purpose of obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
In addition, as used herein, the term "health functional food" refers to a food manufactured and processed using a specific ingredient as a raw material or a food manufactured and processed by extracting, concentrating, refining, mixing specific ingredients contained in food ingredients as raw materials for the purpose of health supplementation, It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, biological rhythm control, disease prevention and recovery, etc. by the above ingredients, and the health food composition can perform functions to prevent diseases (equivalent designatable as disorders) and prevent diseases (equivalent designatable as disorders), etc.
There is no limitation on the type of food or nutraceutic in which the composition of the present invention can be used for the prevention and/or amelioration of obesity and/or metabolic diseases (equivalent designatable as disorders). In addition, the composition comprising the Narcissus spp. plant extracts of the present invention as an active ingredient may be prepared by mixing suitable other auxiliary ingredients and known additives that may be contained in food according to the choice of a person skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, and the like. Furthermore, foods can be prepared by adding the extract and fraction thereof according to the present invention as a main component to other extracts, tea, jelly, juice,
and the like.
In addition, foods that can be applied to the present invention include, for example, special nutritional foods (e.g., milk formula, infants/baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), health supplement foods, seasoned foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, sweets (e.g., snacks), dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.) ), beverages (e.g., fruit, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.).
The content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15% by weight, more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition. When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweetening agents, flavoring agents, natural carbohydrates, and the like as an additional component, as in ordinary beverages. In addition to the above, the health functional food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agent used in carbonated beverages, etc. In addition, it may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, and vegetable beverage.
In another embodiment, the present invention provides a cosmetic composition for preventing or ameliorating obesity comprising a the Narcissus spp. plant extract (e.g., an extract of the aerial parts the Narcissus spp. plant). The Narcissus spp. plant extract and its preventive and therapeutic effects on obesity are as described above.
The cosmetic composition of the present invention can be used for the purpose of preventing and ameliorating obesity. The cosmetic composition can be generally used for areas such as thighs and buttocks in which cellulite formed by excessive adipocyte differentiation and accumulation of lipids in adipocyte is excessively distributed, and the cosmetic composition is not limited to the area and can be applied to any area in which adipocytes are developed.
In the present invention, the component contained in the "cosmetic composition" may include ingredients commonly used in cosmetic compositions in addition to the active ingredient. For example, it contains the conventional adjuvant such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, and the carrier. The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream and spray may be formulated, but is not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
When the formulation of the present invention is the paste, cream or gel, animal oil,
vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used as the carrier ingredient.
When the formulation of the present invention is the solution or turbid fluid, the solvent, solubilizing agent or emulsifying agent can be utilized as a carrier ingredient, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-buthylglycol oil, glycerol aliphatic ester, polyethylene glycol or aliphatic ester of sorbitan, etc. can be utilized as the carrier ingredient.
When the formulation of the present invention is suspension, the liquid diluents such as water, ethanol or propylene glycol, suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, ortragacant, etc. can be utilized as the carrier ingredient.
When the formulation of the present invention is the powder or spray, the lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder can be utilized as a carrier ingredient, and in particular when it is a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether can be additionally included.
When the formulation of the present invention is the surfactant-containing cleansing, the aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulphosuccinic monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivative or ethoxylated glycerol fatty acid ester, etc. can be utilized as the carrier ingredient.
When the cosmetic composition of the present invention is the soap, cleansing formulation containing a surfactant or cleansing formulation containing no surfactant, it may be applied to the skin and then wiped off, removed, or washed off with water. As a specific example, the soap is liquid soap, powder soap, solid soap and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream, cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
The content of Narcissus spp. plant extracts contained in the above composition is not specifically limited, but can be contained in an amount of 0.00001 to 100% by weight, preferably 0.0001 to 15 wt%, more preferably 0.001 to 15% by weight, and even more preferably 0.001 to 10% by weight, based on the total weight of the composition.
The above-described composition comprising the Narcissus spp. plant extract of the present invention may be considred as a natural medicinal plant as a raw material. Therefore even when used as a pharmaceutical composition, food or nutraceutical composition, skin external preparation composition or cosmetic composition, side effects may be less compared to general synthetic compounds, and so it is safely included and can be usefully used.
The present invention also refers to use of a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for controlling weight gain of a subject, preferably wherein the use is conducted as described herein.
It will be understood that the definitions and preferred embodiments made in the context of the method and composition of the present invention mutatis mutandis apply to the use of the present invention. The use may be any use, including a cosmetic use (also: non- pharmaceutical, non-therapeutic) or a therapeutic (also: pharmaceutical) use.
The present invention also refers to a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for use in a method of controlling weight gain of a subject, in particular wherein the subject suffers from or is at risk of a disease associated with over-weight, in particular for treating or preventing obesity or metabolic syndrome, preferably wherein the method is conducted as described herein.
It will be understood that the definitions and preferred embodiments made in the context of the method and composition of the present invention mutatis mutandis apply to the composition for use of the present invention.
Advantageous Effects
The Narcissus spp. plant extract (e.g., extract of the aerial parts of Narcissus spp. plant) which is the active ingredient of the present invention is highly safe to humans without having skin irritation and cytotoxicity, and may inhibit adipocyte differentiation, reduce the number of adipocytes, and accumulation and excessive secretion of lipids, and thus may be effectively used for a pharmaceutical composition, a food or nutraceutical composition, a skin external preparation composition and a cosmetic composition for the prevention, amelioration and treatment of obesity and/or metabolic syndrome. In particular, the Narcissus spp. plant extract (e.g., extract of the aerial parts of Narcissus spp. plant) may be
effectively applied for the purpose of inhibiting the accumulation and excessive secretion of lipids in areas with abundant adipocytes, including areas such as thighs, underarms, abdomen, hips and buttocks, where cellulite produced due to excessive adipocyte differentiation is excessively distributed. More generally, the extract of the aerial parts of Narcissus spp. plant of the present invention may be effective in managing the adipose tissue inflammation and homeostasis in overweight context. In addition, the extract of the aerial parts of Narcissus spp. plant may be effective in restoring the adipose tissue homeostasis.
Description of Drawings
FIG. 1 shows the results of measuring the effect of Narcissus spp. extracts according to the present invention on the inhibition of lipids accumulation in 3T3-L1 adipocytes. The results demonstrate the inhibition effect of Narcissus spp. extracts on the inhibition of the differentiation of 3T3-L1 preadipocytes into adipocytes. These results demontrate the effects of Narcissus tazetta L. extract, Narcissus Pseudo-Narcissus L extract, and Narcissus jonquilla L. extract compared to caffeine.
FIG. 2 shows the results of quantifying the effect of Naricissus spp. extracts according to the present invention on lipolysis of differentiated 3T3-L1 adipocytes. FIG. 2 demonstrates the effect of Narcissus tazetta L., Narcissus Pseudo-Narcissus L and Narcissus jonquilla L. extracts compared to caffeine. These results demonstrate the lipolytic effect of Narcissus spp. extracts.
FIG. 3 shows the results of measuring the effect of a Narcissus tazetta L., Narcissus jonquilla L. or Narcissus Pseudo-Narcissus L extract according to the present invention on
the inhibition of triglycerides accumulation in 3T3-L1 adipocytes.
FIG. 4 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention, in comparison to the caffeine, on the release of glycerol by 3T3-L1 adipocytes. The results demonstrate the lipolytic effect of Narcissus jonquilla L. extract that is is stronger than caffeine.
FIG. 5 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the release of glycerol by human fully mature adipocytes. The results confirm the lipolytic effect, as demonstrated in Fig. 4, of Narcissus jonquilla L. extract on fully mature adipocytes.
FIG. 6 and 7 show the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the fibro-inflammation of human pre-adipocytes in inflammatory condition by quantifying IL-6 and procollagen-l releases.
FIG. 8 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the expression of the biological markers (collagen I, Elastin, MMP-1 and MMP-9) by the immature 3T3-L1 adipocytes. These markers are important for the physiology and structure of the skin. It is known that these markers are also deregulated in a tissue fibrosis context such as keloids, scleroderma and hypertrophic scarring.
FIG. 9 shows the results of measuring the effect of a Narcissus jonquilla L. extract according to the present invention on the browning promoting effect in 3T3-L1 adipocytes
by the stimulation of 2 mitochondrial markers UCP-1 and TFAM.
FIG. 10 shows the results (microscopic images) of performing Oil-red 0 staining to observe the effects of a Narcissus spp. extracts (Narcissus tazetta L, Narcissus jonquilla L. or Narcissus Pseudo-Narcissus L extract) according to one embodiment of the present invention on the inhibition of the differentiation of 3T3L1 preadipocytes into adipocytes. A-D show cell images. E-F show Oil-Red 0 staining. A and E show control (day 0-9), B and F show activity of 50 pg/mL Narcissus tazetta extract, C and G show activity of 50 pg/mL Narcissus jonquilla extract, and D and FI show activity of 50 pg/mL Narcissus Pseudo- Narcissus extract. hereinafter, the present specification will be described in detail with reference to examples to understand the present invention. However, the examples according to the present specification can be modified in various forms, and it is not to be interpreted that the scope of the present specification is limited to the examples described below. The examples of the present specification are provided to more completely explain the present invention to a person skilled in the art.
Example 1 : Production of Narcissus spp. plant extracts
An aerial part of each of Narcissus tazetta L., Narcissus jonquilla L. and Narcissus Pseudo- Narcissus L. plants was washed clean, dried in shade at 20°C to 35°C, and then pulverized to powder having a particle size of 1 mm or less. Thereafter, 100 g of the powder of the aerial part (e.g., stem, leaf, and flower) of each Narcissus spp. plant was immersed in a 70% ethanol solvent, and then subjected to ultrasonic extraction for 48 hours, and the resulting extract was filtered through filter paper (Advantec No.2). The filtrate was
concentrated under reduced pressure to obtain an ethanol extract of the aerial part of each Narcissus spp. plant.
For the following examples, the Narcissus spp. extracts obtained according to the example 1 are used for all of the experiments. It could be assumed that all of the Narcissus spp. extract obtained in the example 1 may reasonably exert the effects as described in the present disclosure.
All data were expressed as mean ± standard deviations. *<0.05, **<0.01 , ***<0.001 were indicated statistically significant.
Example 2: Adipocyte differentiation inhibitory effect of Narcissus spp. plant extracts To evaluate the adipocyte differentiation inhibitory effect of each of the Narcissus spp. plant extracts, the following experiment was conducted.
Specifically, (immature) adipocytes (3T3-L1 ) purchased from ATCC (American Tissue Culture Collection, USA) were prepared and cultured in a DMEM medium containing 10% by weight BCS (Bovine Calf Serum). For differentiation into adipocytes, the (immature 3T3- L1 ) adipocytes were seeded into a 6-well plate at a density of 1 x105 cells and then cultured in 10% by weight BCS-containing DMEM medium at 37°C under 5% CO2 until the cells reached confluence in each well. Then, the cells were further cultured for 2 days and were treated with an MDI cocktail (0.5 mM isobutylmethylxanthin, 1 mM dexamethason and 1 pg/mL insulin). After 3 days, the medium was replaced with a medium containing 1 pg/mL of insulin, and after 3 days again, was replaced with a DMEM medium containing 10% by weight FBS (fetal bovine serum). From the time point when differentiation was induced by
treatment with the MDI cocktail, the cells were also treated with the test sample (Narcissus spp. extracts) or caffeine, and then retreated with the same concentration of the test sample every time the culture medium was replaced. To measure the amount of lipids accumulated in the differentiated cells, the lipids were stained by Oil Red 0 staining and dissolved with isopropyl alcohol, and then the optical density at 540 nm was measured.
As a result, as can be seen in FIG. 1 , it could be confirmed that, when immature 3T3-L1 adipocytes were treated with MDI, differentiation into adipocytes was induced and lipids were accumulated in the cells, and that the Narcissus spp. plant extracts inhibited differentiation into adipocytes in a concentration-dependent manner, so that lipids were not accumulated in the cells.
Furthermore, it was demonstrated that the inhibitory effect of Narcissus jonquilla L extract is, for example, 80 times higher than caffeine at 5 ppm for Narcissus jonquilla extract vs. 400 ppm for the caffeine for obtaining 80% of reduction of the lipids in differentiated 3T3-L1 adipocytes. Taken together, these experimental results demonstrate the efficacy of the Narcissus spp. plant extract in exerting a slimming effect and controlling the weight gain.
Example 3: Lipolysis-stimulating effect of Narcissus spp. plant extract As described in Example 2 above, immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. After 9 days of induction of differentiation, DMEM medium containing 10% by weight FBS was treated with various concentrations of the Narcissus spp. plant extracts or caffeine. To measure the amount of lipids accumulated in the differentiated cells (3T3-L1 adipocytes), the lipids were stained by Oil Red O staining and dissolved with isopropyl alcohol, and then the optical density at 540 nm was measured
and quantified.
As a result, as can be seen in FIG. 2, it could be confirmed that the Narcissus spp. plant extracts concentration-dependently stimulated the degradation of lipids accumulated in the adipocytes. Moreover, caffeine is harboring a similar effect, but only at high concentration compared to the Narcissus spp. extracts. In view of the above, it was experimentally found that Narcissus spp. extracts of the present invention can be used as an active slimming ingredient.
Example 4: Triglyceride inhibitory effect of Narcissus spp. plant extract As described in Example 2 above, immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. Then, the amount of triglycerides produced in the cells was determined using a triglyceride determination kit (Sigma, USA).
As a result, as can be seen in FIG. 3, it could be confirmed that the amount of triglycerides in the group treated with the Narcissus spp. plant extract decreased in a concentration- dependent manner, confirming its ability to induce the slimming effect and controlling the overweight gain.
Example 5: Glycerol release stimulating effect of Narcissus jonquilla L. extract As described in Example 2 above, immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. Then, the release of glycerol by the cells was determined using a glycerol assay kit. As a result, as can be seen in FIG. 4, it could be confirmed that the release of glycerol in the group treated with the Narcissus jonquilla L. extract increases in a concentration-dependent manner. In parallel, caffeine induces similar
effect at highly concentration compared to the Narcissus jonquilla L extract, demonstrating the slimming benefit effect of the extract of Narcissus jonquila L. compared to caffeine.
Example 6: Narcissus jonquilla L. extract stimulates the lipolysis of fully mature human adipocytes
Cells were isolated from adipose tissue of an obese woman of 27-year-old, body mass index (BMI) = 33.5 kg/m2, by collagenase digestion under gentle agitation. Adipocytes were washed with a sucrose solution and then incorporated into a peptide hydrogel. Adipocytes capsules of 25 pi were formed and cultivated in specific medium with Narcissus jonquilla L. extract for 24 h before medium collection for glycerol release evaluation. It is agreed in the art that the encapsulated fully mature adipocytes 3D model gets closer to the physiological properties of the cells and allows a suitable response to pro-lipolytic stimuli. As a result, as can be seen in FIG. 5, it could be confirmed that the release of glycerol in the group treated with the Narcissus jonquilla L. extract increases in a concentration-dependent manner, demonstrating that the extract of Narcissus jonquilla L. can be used as an active slimming ingredient
Example 7: Evaluation of the effects of the Narcissus jonquilla L. extract on fibro- inflammatory preadipocytes
Preadipocytes were isolated from human female obese adipose tissue (39-year-old,
BMI = 31.6 kg/m2). Preadipocytes were cultured for 24 h in 100 mI of DMEM-10% by weight Fetal Bovine Serum (FBS) in 96-well plates. To induce the preadipocytes differentiation in fibro-inflammatory environment, cells were treated with a proadipogenic cocktail including insulin, glucocorticoid, 3-isobutyl-1 -methylxanthine (IBMX), and thiazolinedione and with a pro-inflammatory cocktail consisting in activated macrophage-conditioned medium (ACMC)
for 14 days. During the last 24 h of culture, the cells were replaced in fresh DMEM/F12 medium to collect cells secretions. Dexamethasone 100 nM was used as anti-inflammatory response control. All conditions were performed in triplicate. The media were changed every 2 days for 14 days.
The aforementioned model of human preadipocytes cultured in an inflammatory context, using macrophages conditioned medium (ACMC), is highly relevant, in the art, to evaluate the beneficial properties of the extract of Narcissus jonquilla L, mainly to assess its ability to reverse the deleterious effects of an inflammatory adipose tissue observed in obesity and in metabolic disorders.
As a result, as can be seen in FIGS. 6 and 7, it could be confirmed that the release of IL-6 and procollagen-l in the group treated with the Narcissus jonquilla L. extract decreases in a concentration-dependent manner. In other words, the ACMC inflammatory environment induced a high increase in IL-6 secretion compared to the differentiation control condition. The secreted IL-6 increase was partially reversed by the dexamethasone, which is a well- known anti-inflammatory molecule. The Narcissus jonquilla L. extract induced a high decrease in IL-6 secretion. This effect is better and significantly different than the dexamethasone. The ACMC inflammatory environment induced a high increase in procollagen-l secretion compared to the differentiation control condition. The dexamethasone induced a decrease in the procollagen-l secretion compared to the ACMC condition. It was demonstrated that the Narcissus jonquilla L. extract induced a higher decrease in the procollagen-l secretion. Taken together, these experimental results demonstrate that the extract of Narcissus jonquilla L. can be used for counteracting or preventing the inflammation of the adipose tissue and tissue fibrosis.
Example 8: Protective effect of Narcissus jonquilla L. extract on the dermal ECM As described in Example 2 above, immature 3T3L1 adipocytes were treated with MDI with or without 50 ppm of Narcissus jonquilla L. extract to induce differentiation for 21 days into enlarged adipocytes. After 21 days of induction of differentiation, supernatants from differentiated adipocyes were collected. Basal fibroblasts were treated 48h with conditioned medium (CM) of differentiated adipocytes treated or not with Narcissus jonquilla L. extract before mRNA extraction. Then, the expression of ECM related gene level (Col1a1 , Elastin, MMP-1 , and MMP-9) were quantified using real-time PCR.
As a result, as can be seen in FIG. 8, it could be confirmed that the Narcissus jonquilla L. extract increased the expression of collagen 1 and elastin decreased by CM of enlarged adipocytes. However, Narcissus jonquilla L. extract inhibited the MMP-1 and MMP-9 expression increased by CM of enlarged adipocytes. Taken together, these results demonstrate the ability of Narcissus jonquilla extract in controlling the dermal ECM components, ameliorating the firmness and elasticity of the skin.
Example 9: Browning promoting effect of Narcissus jonquilla L. extract As described in example 2 above, immature 3T3-L1 adipocytes were treated with MDI to induce differentiation into adipocytes. After 9 days of induction of differentiation, DMEM medium containing 10% by weight FBS was treated with various concentrations of Narcissus Jonquilla extract. To measure the expression of UCP-1 and TFAM, real-time PCR was used for quantification of mRNA levels. As a result, as can be seen in FIG. 9, it could be confirmed that the Narcissus jonquilla L. extract upregulated the UCP-1 and
TFAM mRNA expression level in the adipocytes. Taken together, these results demonstrate the ability of Narcissus jonquilla L. extract as a slimming ingredient.
Example 10: Test for identifying the safety of Narcissus spp. plant extract to the human skin 10 1
Preparation of skin external formulation containing Narcissus spp. extract To identify as to whether Narcissus spp. plant extract, which is proven to be excellent in inhibiting the adipocyte's lipid production as described above, is safe or not for human skin, skin external formulations containing Narcissus spp. plant extract were prepared, and then a skin safety verification test was carried out.
Skin external formulation containing Narcissus spp. plant extract was prepared by the formulations in Table 1 below.
For skin external formulation, purified water, glycerin, and butylene glycol were mixed and dissolved at a temperature of 70°C (aqueous phase). The remaining components except for the above three components and trimethanolamine were dissolved at a temperature of 70°C (oil phase). The oil phase was added to the aqueous phase and stirred with a homomixer (Tokushu Kika, Japan) to prepare an emulsion, and trimethanolamine was added thereto. Then, bubbles produced in the mixture were removed, after which the mixture cooled to room temperature, thereby preparing the skin external formulation.
Table 1
10-2. Cumulative irritation test
Each of the skin external formulations prepared in Example 10-1 above was applied every other day to the forearms of 30 healthy adults and allowed to stand for 24 hours. The test was repeated so that each subject was treated with 9 fresh patches in total, so as to confirm whether Narcissus spp. plant extract irritates the skin.
As a patch method, Finn chamber (Epitest Ltd, Finland) was used. After loading each of the above skin external formulations of 15ul each into the chamber, the patch was carried out. The level of reaction each time on the skin was graded using the following empirical formula 1 , and the result was shown in the following Table 2
Empirical formula 1
Average response degree = [[Response index X Response degree / Total number of subjects X Highest score (4 points)] X 100] / Number of examinations Regarding the response degree, 1 point was provided for ±, 2 points for +, and 4 points for ++. When the average response degree was less than 3, the composition was determined to be safe for use on the skin.
As a result of Table 2, in the test group, the subjects corresponding to ±, +, and ++ numbered 1 , 0 and 0, respectively, and no skin response appeared. As a result of calculating the [(1 X2)/(20X4)]X100/9=0.13, the mean reaction degree for the Test group is 0.13, test group is all less than 3, suggesting that the composition of the present invention is safe for use on human skin.
As described in Table 2 above, external skin formulation containing Narcissus spp. plant extract (test groups) did not show any apparent cumulative irritation and were determined
to be safe for human skin.
Formulation Example 1 : Cosmetic formulations Formulation Example 1 -1. Preparation of skin softener
As shown in Table 3 below, a skin softener containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
Formulation Example 1-2. Preparation of nourishing softener
As shown in Table 4 below, a nourishing softener containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
Table 4
Formulation Example 1-3. Preparation of nourishing cream
As shown in Table 5 below, a nourishing cream containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
Formulation Example 1-4. Preparation of massage cream
As shown in Table 6 below, a massage cream containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
As shown in Table 7 below, a pack containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
Preparation Example 2: Preparation of pharmaceutical formulations Preparation Example 2-1 : Preparation of powder formulation
The above components were mixed and filled into a sealed bag to produce a powder formulation.
Preparation Example 2-2: Preparation of tablet formulation
Table 9
The above components were mixed and then compressed to a tablet according to a conventional method.
Preparation Example 2-3. Capsule formulation
The above components were mixed and then filled into a gelatin capsule to a conventional method.
The above components were mixed, and a gel containing Narcissus spp. plant extract as an active ingredient was prepared according to a conventional method.
Preparation Example 2-5. Ointment production
Preparation Example 3: Preparation of Food
Preparation Example 3-1 : Preparation of Flour Food The Narcissus spp. plant extract of the present invention was added 0.5 to 5.0 parts by weight to flour, and the mixture prepared bread, the mixture prepared cakes, cookies, crackers, and noodles.
Preparation Example 3-2: Preparation of Soup and Gravies 0.1 to 5.0 parts by weight of Narcissus spp. plant extract of the present invention were added to soup and gravies, and then meat products, noodle soup, and gravies for health promotion were prepared.
Preparation Example 3-3: Preparation of Ground Beef
10 parts by weight of Narcissus spp. plant extract of the present invention were added to ground beef to prepare to ground beef for health promotion.
Preparation Example 3-4: Preparation of Dairy Products
5 to 10 parts by weight of Narcissus spp. plant extract of the present invention were added to milk, and various dairy products, such as butter and ice cream, were prepared using the milk
Preparation Example 3-5: Preparation of Sausage
As shown below, sausage food products containing Narcissus spp. plant extract of the
present invention were manufactured. Pork 65.18w%, chicken 25% by weight, starch 3.5% by weight, soybean protein 1.7% by weight, table salt 1.62% by weight, glucose 1.4% by weight, glycerin 1.5% by weight, and Narcissus spp. plant extract 0.1 % by weight of the present invention were mixed to prepare sausages according to a conventional method.
Preparation Example 3-6: Preparation of healthy beverages The supplementary ingredients were homogeneously mixed with 5 g of Narcissus spp. plant extract of the present invention. The above supplementary ingredients are such as high fructose corn syrup (0.5% by weight), oligosaccharide (2% by weight), sugar (2% by weight), edible salt (0.5% by weight), and water (75% by weight). After flash pasteurization, the healthy beverage was prepared by packaging in a small packaging container such as a glass bottle, plastic bottle, etc.
Preparation Example 3-7: Preparation of vegetable juice
Vegetable juice was prepared by adding 5 g of Narcissus spp. plant extract of the present invention to 1 ,000 ml_ of tomato or carrot juice.
Preparation Example 3-8: Preparation of fruit juice
Fruit juice was prepared by adding 1 g of Narcissus spp. plant extract of the present invention to 1 ,000 ml_ of apple or grape juice.
Further embodiments of the present invention refer to the following:
[Embodiment 1 ]
A pharmaceutical composition for preventing or treating obesity or metabolic syndrome
comprising, as an active ingredient, at least one Narcissus spp. plant extract selected from the group consisting of a Narcissus tazetta L. extract, a Narcissus jonquilla L. extract and a Narcissus Pseudo-Narcissus L. extract. [Embodiment 2]
The pharmaceutical composition of embodiment 1 , wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome. [Embodiment s]
A food composition for preventing or ameliorating obesity or metabolic syndrome comprising a Narcissus spp. plant extract as an active ingredient.
[Embodiment 4] The food composition of embodiment 3, wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
[Embodiment s] A skin external preparation composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract as an active ingredient.
[Embodiment s]
The skin external preparation composition of embodiment 5, which is applied to a subject’s
area having cellulite formed due to excessive adipocyte differentiation and accumulation of lipids in adipocytes.
[Embodiment /]
A cosmetic composition for preventing or ameliorating obesity comprising a Narcissus spp. plant extract as an active ingredient.
[Embodiment s]
The cosmetic composition of embodiment 7, which is applied to a subject’s area having cellulite formed due to excessive adipocyte differentiation and accumulation of lipids in adipocytes.
[Embodiment 9]
Composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
[Embodiment 10]
Use of a composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient.
[Embodiment 11 ]
Composition according to embodiment 9 or use according to embodiment 10, wherein the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L., and Narcissus Pseudo-Narcissus L.
[Embodiment 12]
Composition according to embodiment 9 or 11 or use according to embodiment 10 or 11 , wherein the aerial part is selected from the group consisting of the leaves, the stems, the flowers, or a combination of two or more thereof.
[Embodiment 13]
Composition according to any of embodiments 9, 11 or 12 or use according to any of embodiments 10 to 12, wherein the Narcissus spp. plant is Narcissus jonquilla L.
[Embodiment 14]
Composition according to any of embodiments 9, 11 to 13 or use according to any of embodiments 10 to 13, wherein the at least one extract of the aerial parts of Narcissus spp. is characterized in that:
(i) it is an aqueous, a hydroalcoholic, or an alcoholic extract; and/or
(ii) it comprises at least 0.05% by weight, preferably at least 0.1 % by weight, more preferably at least 0.15% by weight, particularly at least 0.2% by weight of dry matter, referred to the total weight of the extract.
[Embodiment 15]
Composition according to any of embodiments 9, 11 to 14 or use according to any of embodiments 10 to 14, wherein the alcohol is selected from the group consisting of ethanol, methanol, propanol, butanol, pentanol, phenol, glycerol, 1,3-butylene glycol, propane diol, or a mixture of two or more thereof.
[Embodiment 16]
Composition according to any of embodiments 9, 11 to 15 or use according to any of embodiments 10 to 15, wherein the composition comprises 0.0001 to 15% by weight, preferably 0.001 to 15% by weight, more preferably 0.001 to 10% by weight, based on the total weight of the composition.
[Embodiment 17]
A cosmetic or pharmaceutical composition comprising: a. at least one extract of the aerial parts of Narcissus spp. as defined in any one of embodiments 9 to 16 as an active slimming ingredient; and b. at least one further cosmetically and/or pharmaceutically acceptable ingredient other than the extract of Narcissus spp., preferably wherein the composition is a composition for topic use selected from the group consisting of a solution, a suspension, an emulsion, a cream, a paste, a gel, a lotion, a powder, a microcapsule, a microgranule, a soap, a surfactant-containing water, an oil, an ointment, and a spray, or wherein the composition is a food or a nutraceutical composition which is administered orally.
[Embodiment 18]
A composition as defined in any of the embodiments 9 to 17 for use for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
[Embodiment 19]
A composition as defined in any of the embodiments 9 to 18 for use for preventing and/or treating a metabolic syndrome. [Embodiment 20]
A composition for use according to embodiment 19, wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid-related metabolic syndrome.
[Embodiment 21 ]
Cosmetic use of a composition comprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant as an active ingredient for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin.
[Embodiment 22]
The cosmetic use according to embodiment 21 , wherein the cosmetic use comprises: - preventing the lipid accumulation by regulating the adipocyte differentiation, inhibiting excessive secretion of adipocyte-derived lipids, stimulating adipocytes lipolysis, promoting the conversion of white adipocytes into brown adipocytes by increasing the expression of UCP-1 and/or TFAM,
controlling the structure of the dermal extracellular matrix by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin, counteracting or preventing the tissue fibrosis by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin; counteracting or preventing the inflammation of the adipose tissue by inhibiting the secretion of IL-6, counteracting or preventing the inflammation-induced ectopic collagen I depots formation in the adipose tissue by inhibiting the synthesis of procollagen-l; controlling the secretion of adipokines from adipose tissue, and a combination of two or more thereof.
[Embodiment 23]
The cosmetic use according to any of embodiments 21 or 22, wherein
A. the Narcissus spp. plant is selected from the group consisting of Narcissus tazetta L, Narcissus jonquilla L, and Narcissus Pseudo-Narcissus L, preferably Narcissus jonquilla L
B. the aerial part is selected from the leaves, the stems, the flowers, or a combination of two or more thereof, preferably the stems and flowers;
C. it is an aqueous, a hydroalcoholic, or an alcoholic extract, preferably alcoholic extract, more preferably ethanolic extract; and/or
D. the use is as defined in any of embodiments 21 or 22.
[Embodiment 24]
A cosmetic method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected
from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of a composition comprising (or consisting of) at least one extract of the aerial parts of Narcissus spp. plant as an active slimming ingredient as defined in any of the embodiments 9 to 17.
Claims
1. A method of controlling weight gain of a subject, said method comprising administering a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient to said subject.
2. The method according to claim 1 , wherein the Narcissus spp. plant is selected from the group consisting of Narcissus jonquilla L, Narcissus tazetta L, and Narcissus Pseudo- Narcissus L, in particular wherein the Narcissus spp. plant is Narcissus jonquilla L.
3. The method according to any of the claims 1 or 2, wherein the aerial part is selected from the group consisting of leaves, the stems, flowers, or a combination of two or more thereof, in particular preferably stems and/or flowers.
4. The method of according to any of the claims 1 to 3, wherein the extract of aerial parts of a Narcissus spp. is an active slimming ingredient.
5. The method of according to any of the claims 1 to 4, wherein it is a method of preventing, ameliorating, or treating obesity and/or metabolic syndrome.
6. The method according to any of the claims 1 to 5, wherein the at least one extract of aerial parts of Narcissus spp. is characterized in that:
(i) it is an aqueous, a hydroalcoholic, or an alcoholic extract, preferably wherein an alcohol contained in a hydroalcoholic or alcoholic extract is selected from the group consisting of ethanol, methanol, propanol, butanol, pentanol, phenol, glycerol,
1 ,3-butylene glycol, propane diol, or a mixture of two or more thereof, in partilcar wherein an alcohol contained in a hydroalcoholic or alcoholic extract is ethanol; and/or
(ii) it comprises at least 0.05% by weight, preferably at least 0.1 % by weight, more preferably at least 0.15% by weight, particularly at least 0.2% by weight of dry matter, referred to the total weight of the extract.
7. The method according to any of the claims 1 to 6, wherein the at least one extract of aerial parts of Narcissus spp. is an aqueous extract which is obtained by extracting the aerial parts of Narcissus spp. with hot water of a temperature of 25 to 200°C, of 50 to
175°C, of 60 to 150°C, of 70 to 140°C, of 80 to 130°C, or of 90 to 120°C, wherein the extraction is preferably conducted under reflux.
8. The method according to any of claims 1 to 7, wherein the composition comprises 0.0001 to 15% by weight, preferably 0.001 to 15% by weight, more preferably 0.001 to
10% by weight, based on the total weight of the composition.
9. The method according to any of claims 1 to 8, wherein the composition is: a. a cosmetic or pharmaceutical composition further comprising at least one further cosmetically and/or pharmaceutically acceptable ingredient other than the extract of Narcissus spp., preferably wherein the composition is a composition for topic use selected from the group consisting of a solution, a suspension, an emulsion, a cream, a paste, a gel, a lotion, a powder, a microcapsule, a microgranule, a soap, a surfactant-containing water, an oil, an ointment, and a spray, and/or b. a food or a nutraceutical composition which is administered orally.
10. The method according to any of the claims 1 to 9, wherein it is a method is:
(a) for preventing and/or treating obesity or fat-related disorders, for preventing and/or alleviating or treating the overweight-related skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight-related skin; and/or
(b) for preventing and/or treating a metabolic syndrome, in particular wherein the metabolic syndrome is one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, and lipid- related metabolic syndrome.
11. The method according to any of the claims 1 to 10, wherein it is a method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight- related skin.
12. The method according to any of the claims 1 to 11 , comprising: preventing the lipid accumulation by regulating the adipocyte differentiation, inhibiting excessive secretion of adipocyte-derived lipids, stimulating adipocytes lipolysis, promoting the conversion of white adipocytes into brown adipocytes by increasing the expression of UCP-1 and/or TFAM, controlling the structure of the dermal extracellular matrix by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin,
counteracting or preventing the tissue fibrosis by controlling the expression of MMP-1 , MMP-9, collagen 1 and elastin; counteracting or preventing the inflammation of the adipose tissue by inhibiting the secretion of IL-6, counteracting or preventing the inflammation-induced ectopic collagen I depots formation in the adipose tissue by inhibiting the synthesis of procollagen-l; controlling the secretion of adipokines from adipose tissue, and/or a combination of two or more thereof.
13. The method according to any of the claims 1 to 12, wherein it is a method for promoting or restoring the adipose tissue homeostasis, for preventing and/or alleviating or treating the overweight-induced skin damages selected from cellulites, lymphedema, striae and tissue fibrosis, and/or for promoting the firmness and the texture of the overweight- related skin by administering to a subject in need, preferably in subject’s area in need, a sufficient amount of the compositioncomprising or consisting of at least one extract of the aerial parts of Narcissus spp. plant.
14. Use of a composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for controlling weight gain of a subject, preferably wherein the use is conducted accoding to the method according to any of claims 1 to 13.
15. A composition comprising or consisting of at least one extract of aerial parts of a Narcissus spp. plant as an active ingredient for use in a method for of controlling weight gain of a subject, in particular wherein the subject suffers from or is at risk of a disease
associated with over-weight, in particular for treating or preventing obesity or metabolic syndrome, preferably wherein the method is according to any of claims 1 to 13.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0069673 | 2020-06-09 | ||
KR1020200069673A KR102411895B1 (en) | 2020-06-09 | 2020-06-09 | Composition for preventing or treating obesity and/or metabolic syndrome comprising Narcissus spp extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021249960A1 true WO2021249960A1 (en) | 2021-12-16 |
Family
ID=76483274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/065200 WO2021249960A1 (en) | 2020-06-09 | 2021-06-08 | Compositions comprising narcissus spp. plant extract and use thereof |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102411895B1 (en) |
WO (1) | WO2021249960A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270375A (en) * | 2022-11-28 | 2023-06-23 | 嘉文丽(福建)化妆品有限公司 | Preparation of narcissus bulb extract and application of narcissus bulb extract in cosmetics |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006025672A (en) * | 2004-07-14 | 2006-02-02 | Hirose Yukihiro | Beverage having body-slenderizing effect |
JP2006036682A (en) * | 2004-07-27 | 2006-02-09 | Yukihiro Hirose | Composition having weight-reducing activity and cosmetic containing the same |
WO2006112366A1 (en) * | 2005-04-18 | 2006-10-26 | Asahi Breweries, Ltd. | Lipopexia inhibitor and food or beverage |
US20070104810A1 (en) * | 2004-02-04 | 2007-05-10 | Dale Kern | Agents for sequestering aging factors and uses thereof |
KR20160114794A (en) | 2015-03-24 | 2016-10-06 | 주식회사 엘지생활건강 | A cosmetic composition for skin improvement comprising bulb extract |
KR101807978B1 (en) | 2013-10-03 | 2017-12-11 | 이엘씨 매니지먼트 엘엘씨 | Methods and compositions for improving the appearance of skin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003160505A (en) | 2001-09-12 | 2003-06-03 | Lion Corp | Food and drink as well as external preparation with body fat reducing effect |
JP4488852B2 (en) * | 2004-09-17 | 2010-06-23 | 味の素ゼネラルフーヅ株式会社 | Composition having body fat reducing action |
-
2020
- 2020-06-09 KR KR1020200069673A patent/KR102411895B1/en active IP Right Grant
-
2021
- 2021-06-08 WO PCT/EP2021/065200 patent/WO2021249960A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070104810A1 (en) * | 2004-02-04 | 2007-05-10 | Dale Kern | Agents for sequestering aging factors and uses thereof |
JP2006025672A (en) * | 2004-07-14 | 2006-02-02 | Hirose Yukihiro | Beverage having body-slenderizing effect |
JP2006036682A (en) * | 2004-07-27 | 2006-02-09 | Yukihiro Hirose | Composition having weight-reducing activity and cosmetic containing the same |
WO2006112366A1 (en) * | 2005-04-18 | 2006-10-26 | Asahi Breweries, Ltd. | Lipopexia inhibitor and food or beverage |
KR101807978B1 (en) | 2013-10-03 | 2017-12-11 | 이엘씨 매니지먼트 엘엘씨 | Methods and compositions for improving the appearance of skin |
KR20160114794A (en) | 2015-03-24 | 2016-10-06 | 주식회사 엘지생활건강 | A cosmetic composition for skin improvement comprising bulb extract |
Non-Patent Citations (12)
Title |
---|
DATABASE WPI Week 200611, Derwent World Patents Index; AN 2006-105334, XP002804296 * |
DATABASE WPI Week 200616, Derwent World Patents Index; AN 2006-149561, XP002804297 * |
EZURE ET AL., EXPERIMENTAL DERMATOLOGY |
ISHIMARU H ET AL: "Food and drink for preventing and treating obesity, comprises seaweeds such as Eucheuma, Gigartina, Chondrus occellatus and/or Rhodymenia blended with plant extract of Rubiakane narcissus, Aubergine and/or Eucalyptus", WPI / THOMSON, 3 June 2003 (2003-06-03), XP002458098 * |
KOPLEMAN P.G., NATURE, vol. 404, 2000 |
MANSON ET AL., NEW ENGLAND J. MED., vol. 333, 1995 |
MAO QIAN-QIAN ET AL: "Effects of several tea extracts on nonalcoholic fatty liver disease in mice fed with a high-fat diet", FOOD SCIENCE & NUTRITION, vol. 9, no. 6, 9 April 2021 (2021-04-09), pages 2954 - 2967, XP055844448, ISSN: 2048-7177, DOI: 10.1002/fsn3.2255 * |
MI-JUNG PARK, KOREAN J PEDIATR, vol. 48, no. 2, 2005 |
MORI ET AL., LIPIDS IN HEALTH DISEASE |
MUST ET AL., JAMA, vol. 282, 1999 |
RAMAESH M ET AL., DARU, 12 September 2018 (2018-09-12) |
REZADOOST MH ET AL., MOL BIOL REP., vol. 46, no. 5, 2019, pages 5131 - 5142 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116270375A (en) * | 2022-11-28 | 2023-06-23 | 嘉文丽(福建)化妆品有限公司 | Preparation of narcissus bulb extract and application of narcissus bulb extract in cosmetics |
Also Published As
Publication number | Publication date |
---|---|
KR102411895B1 (en) | 2022-06-24 |
KR20210153180A (en) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR102204346B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
WO2021249960A1 (en) | Compositions comprising narcissus spp. plant extract and use thereof | |
JP6055667B2 (en) | Collagen production promoter | |
CN116249514A (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as active ingredient | |
KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
KR101757841B1 (en) | Composition for inhibiting obesity comprising complex salt of baicalin and zinc | |
KR101436213B1 (en) | Compositions for prevention and/or treatment of obesity comprising extracts of Boehmeria sieboldiana | |
KR102502445B1 (en) | Composition for preventing or treating obesity and/or metabolic syndrome comprising Albizia julibrissin extracts | |
KR20220014372A (en) | Composition for inhibiting sebum secretion comprising ellagic acid extract as an active ingredient | |
JP5362976B2 (en) | Blood flow improver | |
KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
KR20220026635A (en) | Composition for preventing or treating obesity and/or metabolic syndrome comprsirng narcissoside | |
KR102475143B1 (en) | Composition for Skin Regeneration Comprising Extract of Vanilla Bean | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
EP3449736B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR101943977B1 (en) | Anti-obesity composition comprising lyophilized Capsicum annuum seed extract as effective component | |
US10406190B2 (en) | Composition and method for treating menopausal symptoms | |
KR101863603B1 (en) | Composition for prevention, improvement or treatment of arthritis comprising Mollugo pentaphylla extract as effective component | |
KR20230168850A (en) | Composition for Promoting Melanin synthesis comprising Sargassum fusiforme extract | |
KR20230096821A (en) | Composition for preventing, ameliorating or treating skin disease comprising Cacalia adenostyloides extract as effective component | |
KR20240005279A (en) | Compositions for inhibiting sebum secretion comprising Sargassum fusiforme extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21732825 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21732825 Country of ref document: EP Kind code of ref document: A1 |